

0001683168-24-00812010-Q Phio Pharmaceuticals Corp. 2021-1142024111416492316492416494 0 0001683168-24-008120 10-Q 53 20240930 20241114 20241114 Phio Pharmaceuticals Corp. 0001533040 2834 000000000 DE 1231 10-Q 34 001-36304 241463715 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 RXI Pharmaceuticals Corp 20111019 10-Q 1 phio i10q-09302024.htm FORM 10-Q FOR SEPT 2024 Phio Pharmaceuticals Corp. 10-Q false -12-31 2024 Q3 0001533040 0001533040 2024-01-01 2024-09-30 0001533040 2024-11-14 0001533040 2024-09-30 0001533040 2023-12-31 0001533040 2024-07-01 2024-09-30 0001533040 2023-07-01 2023-09-30 0001533040 2023-01-01 2023-09-30 0001533040 phio:PreferredStockSeriesDMember 2023-12-31 0001533040 us-gaap:CommonStockMember 2023-12-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001533040 us-gaap:RetainedEarningsMember 2023-12-31 0001533040 phio:PreferredStockSeriesDMember 2024-03-31 0001533040 us-gaap:CommonStockMember 2024-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001533040 us-gaap:RetainedEarningsMember 2024-03-31 0001533040 us-gaap:CommonStockMember 2024-06-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001533040 us-gaap:RetainedEarningsMember 2022-12-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001533040 us-gaap:RetainedEarningsMember 2022-12-31 0001533040 2022-12-31 0001533040 phio:PreferredStockSeriesDMember 2023-03-31 0001533040 us-gaap:CommonStockMember 2023-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001533040 us-gaap:RetainedEarningsMember 2023-03-31 0001533040 phio:PreferredStockSeriesDMember 2023-06-30 0001533040 us-gaap:CommonStockMember 2023-06-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001533040 us-gaap:RetainedEarningsMember 2023-06-30 0001533040 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001533040 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001533040 phio:PreferredStockSeriesDMember 2024-04-01 2024-06-30 0001533040 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001533040 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001533040 phio:PreferredStockSeriesDMember 2024-07-01 2024-09-30 0001533040 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001533040 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001533040 phio:PreferredStockSeriesDMember 2023-01-01 2023-03-31 0001533040 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001533040 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001533040 phio:PreferredStockSeriesDMember 2023-04-01 2023-06-30 0001533040 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001533040 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001533040 phio:PreferredStockSeriesDMember 2023-07-01 2023-09-30 0001533040 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001533040 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001533040 phio:PreferredStockSeriesDMember 2024-09-30 0001533040 us-gaap:CommonStockMember 2024-09-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001533040 us-gaap:RetainedEarningsMember 2024-09-30 0001533040 phio:PreferredStockSeriesDMember 2023-09-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001533040 us-gaap:RetainedEarningsMember 2023-09-30 0001533040 2023-09-30 0001533040 2024-07-04 2024-07-05 0001533040 phio:ClinicalCoDevelopmentAgreementMember phio:AgonOxMember 2024-09-30 0001533040 phio:ClinicalCoDevelopmentAgreementMember phio:AgonOxMember 2024-07-01 2024-09-30 0001533040 phio:ClinicalCoDevelopmentAgreementMember phio:AgonOxMember 2023-07-01 2023-09-30 0001533040 phio:ClinicalCoDevelopmentAgreementMember phio:AgonOxMember 2023-01-01 2023-09-30 0001533040 us-gaap:CashAndCashEquivalentsMember 2024-09-30 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0001533040 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001533040 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001533040 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-03-01 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-02-29 2024-03-01 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-01-01 2024-09-30 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember phio:LaboratoryFacilityMember 2024-07-01 2024-09-30 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember phio:LaboratoryFacilityMember 2024-01-01 2024-09-30 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-09-30 0001533040 phio:May2024FinancingMember 2024-05-16 0001533040 phio:May2024FinancingMember 2024-05-15 2024-05-16 0001533040 phio:July2024FinancingMember 2024-07-11 0001533040 phio:July2024FinancingMember phio:SeriesCWarrantsMember 2024-07-11 0001533040 phio:July2024FinancingMember phio:SeriesDWarrantsMember 2024-07-11 0001533040 phio:July2024FinancingMember 2024-07-10 2024-07-11 0001533040 phio:EquityClassifiedWarrantsMember 2024-07-01 2024-07-31 0001533040 phio:PlacementAgentWarrantsMember 2024-07-01 2024-07-31 0001533040 phio:July2024AbeyanceSharesMember phio:July2024InducementLetterAgreementMember 2024-07-01 2024-09-30 0001533040 phio:April2023FinancingMember 2023-04-19 2023-04-20 0001533040 phio:April2023FinancingMember 2023-04-20 0001533040 phio:April2023FinancingMember phio:SeriesBWarrantsMember 2023-04-20 0001533040 phio:April2023FinancingMember phio:PlacementAgentWarrantsMember 2023-04-20 0001533040 phio:April2023FinancingMember phio:WarrantAmendmentAgreementsMember phio:PreviouslyIssuedWarrantsMember 2023-04-19 2023-04-20 0001533040 phio:April2023FinancingMember phio:WarrantAmendmentAgreementsMember phio:PreviouslyIssuedWarrantsMember 2023-04-20 0001533040 phio:June2023FinancingMember phio:RegisteredSharesMember 2023-06-01 2023-06-02 0001533040 phio:June2023FinancingMember phio:UnregisteredSharesMember 2023-06-01 2023-06-02 0001533040 phio:June2023FinancingMember phio:UnregisteredSharesMember 2023-06-01 0001533040 phio:June2023FinancingMember phio:UnregisteredPreFundedWarrantsMember 2023-06-02 0001533040 phio:June2023FinancingMember phio:SeriesAWarrantsMember 2023-06-02 0001533040 phio:June2023FinancingMember phio:PlacementAgentWarrantsMember 2023-06-02 0001533040 phio:June2023FinancingMember 2023-06-01 202

[illegible]

the July 2024 Inducement Letter Agreements, these warrants were exercised for cash at a reduced exercise of \$5.45 per share in consideration of the Company’s agreement to issue new unregistered five and one-half year term Series C warrants to purchase up to 583,098 shares of common stock at an exercise price of \$5.45 and new unregistered eighteen month term Series D warrants to purchase up to 507,474 shares of common stock at an exercise price of \$5.45, both issued and sold at a price of \$0.125 per warrant share (the July 2024 Financing). In addition, the Company issued warrants to the placement agent, HCW, to purchase a total of 40,896 shares of common stock at an exercise price of \$6.8125 per share. The net proceeds to the Company from the July 2024 Financing were approximately \$2,646,000, after deducting placement agent fees and offering expenses. The Company incurred non-cash equity issuance cost of approximately \$2.4 million for the incremental fair value of the outstanding equity classified warrants and approximately \$0.2 million for placement agent warrants. A Pursuant to the terms of the July 2024 Inducement Letter Agreements, in the event that the exercise of the existing warrants in the July 2024 Financing would have otherwise caused a holder to exceed the beneficial ownership limitations set forth in the existing warrant, the Company issued the number of shares that would not cause a holder to exceed such beneficial ownership limitation and agreed to hold such balance of shares of common stock in abeyance. Accordingly, an aggregate of 328,758 shares of common stock were held in abeyance (the July 2024 Abeyance Shares) with such July 2024 Abeyance Shares evidenced through the holder’s existing warrants and which are deemed to be prepaid. The July 2024 Abeyance Shares were held until notice was received by the holder that the balance of the shares of common stock could be issued in compliance with such beneficial ownership limitations and were exercised pursuant to a notice of exercise from the holder. Until such time, the Abeyance Shares were evidenced through the holder’s existing warrants and have been included in the Company’s table of outstanding warrants below. During the three months ended September 30, 2024, 231,758 of the July 2024 Abeyance Shares were released. The remainder of the July 2024 Abeyance Shares were subsequently released in October 2024. A April 2023 Financing On April 20, 2023, the Company completed a registered direct offering and a concurrent private placement of a total of: 39,331 registered shares of the Company’s common stock at a purchase price per share of \$50.85, unregistered five and one-half year term Series A warrants to purchase up to 39,331 shares of common stock at an exercise price of \$48.60 per share and unregistered eighteen month term Series B warrants to purchase up to 39,331 shares of common stock at an exercise price of \$48.60 per share (collectively, the April 2023 Financing). In addition, the Company issued unregistered warrants to the placement agent, H.C. Wainwright & Co., LLC (the HCW), in the April 2023 Financing to purchase a total of 2,950 shares of common stock at an exercise price of \$63.56 per share. Net proceeds to the Company from the April 2023 Financing were \$1,538,000 after deducting placement agent fees and offering expenses. A In connection with the April 2023 Financing, the Company entered into warrant amendment agreements (the Warrant Amendment Agreements) with the participating investors to amend the exercise price of certain existing warrants to purchase up to an aggregate of 21,291 shares of common stock that were previously issued in April 2018 through January 2021, such that each of the amended warrants have an exercise price of \$48.60 per share. The Company received \$23,952 as consideration in connection with the Warrant Amendment Agreements. The Company assessed the amendments to the exercise price of the warrants under ASC Topic 815, Derivatives and Hedging (the ASC 815) and determined that the amendment to the exercise price was completed in connection with and contingent on the close of the April 2023 Financing. The increase in fair value of \$293,000 related to the Warrant Amendment Agreements was recognized as an equity issuance cost and recorded in additional paid in capital per ASC 815. A June 2023 Financing On June 2, 2023, the Company completed a registered direct offering and a concurrent private placement of a total of: 25,961 registered shares and 8,000 unregistered shares of the Company’s common stock each at a purchase price per share of \$38.52, unregistered pre-funded warrants to purchase up to an aggregate of 69,881 shares of common stock at a purchase price per share of \$38.511 and with a pre-funded warrant exercise price of \$0.009 per share, unregistered five and one-half year term Series A warrants to purchase up to an aggregate of 103,842 shares of common stock at an exercise price of \$36.27 per share and unregistered eighteen month term Series B warrants to purchase up to an aggregate of 103,842 shares of common stock at an exercise price of \$36.27 per share (collectively, the June 2023 Financing). In addition, the Company issued unregistered warrants to the placement agent, HCW, in the June 2023 Financing to purchase a total of 7,788 shares of common stock at an exercise price of \$48.15 per share. Net proceeds to the Company from the June 2023 Financing were \$3,510,000 after deducting placement agent fees and offering expenses. A A 12A A December 2023 Financing In December 2023, the Company entered into an inducement letter agreement (the December 2023 Inducement Letter Agreement) with certain holders of the Company’s existing warrants to purchase up to an aggregate of 236,695 shares of the Company’s common stock (the December 2023 Financing). Pursuant to the terms of the December 2023 Inducement Letter Agreement, in the event that the exercise of the existing warrants in the December 2023 Financing would have otherwise caused a holder to exceed the beneficial ownership limitations set forth in the existing warrant, the Company issued the number of shares that would not cause a holder to exceed such beneficial ownership limitation and agreed to hold such balance of shares of common stock in abeyance. Accordingly, an aggregate of 91,820 shares of common stock were held in abeyance (the December 2023 Abeyance Shares) with such December 2023 Abeyance Shares evidenced through the holder’s existing warrants and which were deemed to be prepaid. The December 2023 Abeyance Shares were held until notice was received by the holder that the balance of the shares of common stock could be issued in compliance with such beneficial ownership limitations and were exercised pursuant to a notice of exercise from the holder. Until such time, the December 2023 Abeyance Shares were evidenced through the holder’s existing warrants and have been included in the Company’s table of outstanding warrants below. A Pursuant to the terms of the Inducement Letter Agreement, in the event that the exercise of the existing warrants in the December 2023 Financing would have otherwise caused a holder to exceed the beneficial ownership limitations set forth in the existing warrant, the Company issued the number of shares that would not cause a holder to exceed such beneficial ownership limitation and agreed to hold such balance of shares of common stock in abeyance. Accordingly, at December 31, 2023, an aggregate of 91,819 shares of common stock were held in abeyance (the Abeyance Shares) with such Abeyance Shares evidenced through the holder’s existing warrants and which are deemed to be prepaid. The Abeyance Shares will be held until notice is received by the holder that the balance of the shares of common stock may be issued in compliance with such beneficial ownership limitations and may be exercised pursuant to a notice of exercise from the holder. Until such time, the Abeyance Shares are evidenced through the holder’s existing warrants and have been included in the Company’s table of outstanding warrants below. The remainder of the December 2023 Abeyance Shares were subsequently released during the first quarter of 2024. A Warrants A The Company first assesses warrants that are issued by the Company under the FASB ASC Topic 480, Distinguishing Liabilities from Equity (the ASC 480) to determine whether the warrants are within the scope of ASC 480. If there are no instances outside of the Company’s control that could require cash settlement, the Company then applies and follows the applicable accounting guidance in ASC 815. Financial instruments are accounted for as either derivative liabilities or equity instruments depending on the specific terms of the agreement. Based on the assessment of the warrants issued by the Company under the guidance in ASC 480 and ASC 815, the warrants issued by the Company have been classified within stockholder’s equity. A During the three months ended September 30, 2024, 231,758 of the July 2024 Abeyance Shares were released and issued. During the three months ended September 30, 2023, 35,588 shares of common stock were issued related to the exercise of pre-funded warrants from the June 2023 Financing. A During the nine months ended September 30, 2024, all of the December 2023 Abeyance Shares were released and issued and 231,758 of the July 2024 Abeyance Shares were released and issued. During the nine months ended September 30, 2023, 55,032 shares of common stock were issued related to the exercise of pre-funded warrants from the June 2023 Financing. A A 13A A A The following table summarizes the Company’s outstanding warrants, all of which are classified as equity instruments, at September 30, 2024: Schedule of outstanding warrants A A A Number of Shares A Weighted-Average Exercise Price Per Share Outstanding at December 31, 2023 A 703,530 A \$35.99 A Issued A 1,131,468 A A 5.50 A Exercised A (540,112) A 6.56 A Expired A A A Outstanding at September 30, 2024 A 1,294,886 A \$21.62 A 6. Stock-based Compensation A Restricted Stock Units A Restricted stock units (the RSUs) are issued under the Company’s 2020 Long-Term Incentive Plan (the 2020 Plan) or as inducement grants issued outside of the 2020 Plan to new employees. RSUs are generally subject to graded vesting and the satisfaction of certain service requirements. RSUs granted by the Company to employees and to non-employee members of the Board of Directors generally vest annually over 1 year after the grant date. Upon vesting, each outstanding RSU will be settled for one share of the Company’s common stock. Employee RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee’s income taxes due upon vesting and withholds a number of shares of equal value. The Company does not expect to repurchase shares to satisfy RSU vests. The fair value of the RSUs awarded are based upon the Company’s closing stock price at the grant date and are expensed over the requisite service period. A On September 11, 2024, the Company modified all unvested RSUs to reduce the vesting term for employees from 3 years after the grant date to 1 year after the grant date. No incremental expense was recognized as a result of the modification, as the fair value of the RSUs immediately before and after the modification was unchanged. A The following table summarizes the activity of the Company’s RSUs for the nine months ended September 30, 2024: Summary of RSU activity A A A Number of Shares A Weighted-Average Grant Date Fair Value Per Share Unvested units at December 31, 2023 A 5,527 A \$74.83 A Granted and accepted A 71,000 A A 2.77 A Vested A (3,997) A 71.10 A Forfeited A (1,530) A 84.55 A Unvested units at September 30, 2024 A 71,000 A \$2.77 A The weighted-average fair value of RSUs granted during both the three and nine months ended September 30, 2024 was \$2.77. A There were no RSUs granted during the three months ended September 30, 2023. During the nine months ended September 30, 2023, 4,833 RSUs were granted. The weighted-average fair value of RSUs granted during the nine months ended September 30, 2023 was \$47.16. A A 14A A A Stock-based compensation expense related to RSUs was \$52,000 and \$89,000 for the three months ended September 30, 2024 and 2023, respectively. Stock-based compensation expense related to RSUs was \$99,000 and \$294,000 for the nine months ended September 30, 2024 and 2023, respectively. A The aggregate fair value of awards that vested during the nine months ended September 30, 2024 and 2023 was \$21,000 and \$100,000, respectively, which represents the market value of the Company’s common stock on the date that the RSUs vested. A Stock Options A Stock options are available for issuance under the 2020 Plan or as inducement grants issued outside of the 2020 Plan to new employees. Stock options are generally subject to graded vesting and the satisfaction of service requirements. Stock options granted by the Company to employees generally vest annually over 4 years after the grant date and generally vest over 1 year after the grant date for non-employee members of the Board of Directors and expire within ten years of grant. Upon the exercise of a stock option, the Company issues new shares and delivers them to the recipient. The Company does not expect to repurchase shares to satisfy stock option exercises. A The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the Company’s own implied volatility. As the Company has limited stock option exercise information, the expected life assumption used for option grants is based upon the simplified method provided for under the FASB ASC Topic 718, Compensation Stock Compensation. The dividend yield assumption is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends. A The Company did not grant any stock options during the three or nine months ended September 30, 2024 and 2023. A The following table summarizes the activity of the Company’s stock options for the nine months ended September 30, 2024: Summary of stock options activity A A A Number of Shares A Weighted-Average Exercise Price Per Share A Aggregate Intrinsic Value Balance at December 31, 2023 A 1,146 A \$10,120.69 A A A Granted A A A Exercised A A A Forfeited A A A Expired A (13) A 598,313.35 A A A Balance at September 30, 2024 A 1,133 A \$3,371.79 A A Exercisable at September 30, 2024 A 1,133 A \$3,371.79 A A A Stock-based compensation expense related to stock options for the nine months ended September 30, 2024 was \$6,000. The Company did not have any stock-based compensation expense related to stock options for the three months ended September 30, 2024 and 2023 or the nine months ended September 30, 2023. A A 15A A A Compensation Expense Related to Equity Awards A The following table sets forth total stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023, in thousands: Schedule of stock-based compensation expense A A A A A Three Months Ended Nine Months Ended A A September 30, 2023 A September 30, 2024 A 2023 Research and development A \$25 A \$51 A \$14 A \$163 A General and administrative A 27 A 38 A 85 A 131 A Total stock-based compensation A \$52 A \$89 A \$99 A \$294 A 7. Net Loss per Common Share A Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing the Company’s net loss by the weighted average number of common shares outstanding and the impact of the dilutive effect of potential common stock equivalents, except when the inclusion of such potential common stock equivalents would be anti-dilutive. Dilutive potential common stock equivalents primarily consist of stock options, RSUs and warrants. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented because the impact of these items is generally anti-dilutive during periods of net loss. A The weighted average number of common shares outstanding as of September 30, 2023 includes the pre-funded warrants issued in connection with the June 2023 Financing, the exercise of which requires nominal consideration for the delivery of the shares of common stock. Therefore, these pre-funded warrants are not included in the table below. A The following table sets forth the potential common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive: Schedule of anti dilutive shares A A A A September 30, A 2024 A 2023 Stock options A 1,133 A A 14 A Unvested RSUs A 71,000 A A 7,694 A Warrants 1,2 A 1,197,886 A A 357,481 A Total A 1,270,019 A A 365,189 A 1 The weighted average number of common shares outstanding as of September 30, 2023 includes pre-funded warrants issued in the June 2023 Financing because the exercise of such warrants requires only nominal consideration. Therefore, these pre-funded warrants are not included in the table above. A 2 The weighted average number of common shares outstanding as of September 30, 2024 includes the Abeyance Shares from the July 2024 Financing, the exercise of which was prepaid and requires no further consideration for the delivery of the shares of common stock. Therefore, 97,000 of these Abeyance Shares are not included in the table above. A 8. Subsequent Events A In accordance with ASC Topic 855, Subsequent Events, which establishes general standards of accounting for and disclosure of events that occur after the consolidated balance sheet date but before the consolidated financial statements are issued, the Company has evaluated all events or transactions that occurred after September 30, 2024, up through the date the Company issued the condensed consolidated financial statements. A A 16A A ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS A In this report, we, the Company, our business operations, Phio Pharmaceuticals Corp. and MirImmune, LLC, whether conducted through Phio Pharmaceuticals Corp. or MirImmune, LLC. A This management’s discussion and analysis of financial condition as of September 30, 2024 and results of operations for the three and nine months ended September 30, 2024 and 2023 should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (the SEC) on April 1, 2024 (the 2023 Form 10-K). A This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as expect, anticipate, believe, intend, plan, forecast, target, predict, could, and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Risks that could cause actual results to vary from expected results expressed in our forward-looking statements include, but are not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, if any, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, results from our preclinical and clinical activities, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, and our ability to obtain future financing. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including those identified in our 2023 Form 10-K under the heading Risk Factors and in other filings the Company periodically makes with the SEC. Therefore, you should not rely

on any of these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q speak as of the date hereof and the Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this report except as required by law. Á Overview Á Phio is a clinical stage biotechnology company whose proprietary INTASYLA® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the bodyâ€™s ability to fight cancer, without the need for specialized formulations or drug delivery systems. Á Cost Rationalization Á In 2023, we implemented a cost rationalization program driven by our transition from a research company to a product development company. This transition resulted in a decision not to renew the lease for our corporate headquarters and primary research facility in Marlborough, Massachusetts, which expired on March 31, 2024. As of April 1, 2024, we have continued operations primarily as a remote business with a laboratory facility in Worcester, Massachusetts. Additionally, we rationalized research personnel and reduced our headcount by approximately 36%. These expense reductions have been redirected to funding the Phase 1b clinical trial with PH-762 directed toward skin cancer. Á Á Á 17A Á Á PH-762 Á PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (â€œPD-1â€œ). PD-1 is a protein that inhibits T cellsâ€™ ability to kill cancer cells and is a clinically validated target in immunotherapy. Decreasing the expression of PD-1 can thereby increase the capacity of T cells, which protect the body from cancer cells and infections, to kill cancer cells. Á Our preclinical studies have demonstrated that direct-to-tumor application of PH-762 resulted in potent anti-tumoral effects and have shown that direct-to-tumor treatment with PH-762 inhibits tumor growth in a dose dependent fashion in PD-1 responsive and refractory models. Importantly, direct-to-tumor administration of PH-762 resulted in activity against distant untreated tumors, indicative of a systemic anti-tumor response. We believe these data further support the potential for PH-762 to provide a strong local immune response without the dose immune-related adverse effects seen with systemic antibody therapy. Á PH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating clinical trial through the intratumoral injection of PH-762 for the treatment of patients with cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. The trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 and is expected to enroll up to 30 patients. In November 2023, we announced the dosing of the first patient under a previously cleared Investigational New Drug (â€œINDâ€œ) application by the U.S. Food and Drug Administration. In May 2024, a safety monitoring committee reviewed data from the first dose cohort treated and recommended the escalation to the next dose concentration. Five (5) patients with cutaneous carcinomas have enrolled in Cohorts 1 and 2. Intratumoral injection of PH-762 has been well tolerated in all patients enrolled in the trial to date. There were no related adverse events, no serious adverse events, and no dose limiting toxicities or dose adjustments. The trial is open for the continued enrollment of patients and expects to complete enrollment of patients in the third quarter of 2025. Á AgonOx Collaboration Á Due to INTASYLâ€™s ease of administration, we have shown that our compounds can easily be incorporated into current adoptive cell therapy (â€œACTâ€œ) manufacturing processes. In ACT, T cells are usually taken from a patient's own blood or tumor tissue, grown in large numbers in a laboratory, and then given back to the patient to help the immune system fight cancer. By treating T cells with our INTASYL compounds while they are being grown in the laboratory, we believe our INTASYL compounds can improve these immune cells to make them more effective in killing cancer. Preclinical data generated in collaboration with AgonOx, Inc. (â€œAgonOxâ€œ), a private company developing a pipeline of novel immunotherapy drugs targeting key regulators of the immune response to cancer, demonstrated that treating AgonOxâ€™s â€œdouble positiveâ€œ tumor infiltrating lymphocytes (â€œDP TILâ€œ) with PH-762 increased their tumor killing activity by two-fold. Á In February 2021, we entered into a clinical co-development collaboration agreement (the â€œClinical Co-Development Agreementâ€œ) with AgonOx to develop a T cell-based therapy using PH-762 and AgonOxâ€™s DP TIL. Under the Clinical Co-Development Agreement, we and AgonOx were working to develop a T cell-based therapy using the our lead product candidate, PH-762, and AgonOxâ€™s DP TIL technology. We had agreed to reimburse AgonOx up to \$4 million in expenses incurred to conduct a Phase 1 clinical trial of PH-762 treated DP TIL in patients with advanced melanoma and other advanced solid tumors. We were also eligible to receive certain future development milestones and low single-digit sales-based royalty payments from AgonOxâ€™s licensing of its DP TIL technology. Á In May 2024, we terminated the Clinical Co-Development Agreement with AgonOx, which such termination was effective immediately. Effective as of the date of termination, the Clinical Co-Development Agreement and our continuing obligations and those of AgonOx thereunder were terminated in their entirety. We are no longer required to provide financial support for the development of costs incurred under the Clinical Co-Development Agreement, and we are no longer entitled to future development milestones or royalty payments from AgonOxâ€™s licensing of its DP TIL technology. We will pay to AgonOx all payment obligations that accrued prior to the termination of the Clinical Co-Development Agreement. Remaining payments to be made to AgonOx as of September 30, 2024 total \$35,000, which primarily relate to accrued obligations for patient fees and other miscellaneous costs as of the date of termination. Pursuant to the terms of the Clinical Co-Development Agreement, we and AgonOx are coordinating the orderly wind-down of the Phase 1 clinical trial. Each of us and AgonOx shall be responsible for its own costs and expenses incurred in connection with the wind-down of the Phase 1 clinical trial. Á Á Á 18A Á Á Prior to the termination of the Clinical Co-Development Agreement with AgonOx, PH-762 treated DP TIL were being evaluated in a Phase 1 clinical trial in the United States with up to 18 patients with advanced melanoma and other advanced solid tumors by AgonOx. The primary trial objectives were to evaluate the safety and to study the potential for enhanced therapeutic benefit from the administration of PH-762 treated DP TIL. AgonOx had enrolled three patients. The first two patients were treated with DP TIL only and the third patient was treated with a combination of DP TIL and PH-762. Á Critical Accounting Policies and Estimates Á The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions and could have a material impact on our reported results. Á There have been no material changes to our critical accounting policies and estimates as compared to those disclosed in our 2023 Form 10-K. Á Results of Operations Á The following data summarizes the results of our operations for the periods indicated, in thousands: Á â€œ Three Months Ended September 30, Á â€œ Nine Months Ended September 30, Á â€œ Description Á 2024 Á 2023 Á Dollar Change Á 2024 Á 2023 Á Dollar Change Operating expenses Á \$ 1,590 Á \$ 2,776 Á \$ (1,186) Á \$ 5,713 Á \$ 8,925 Á \$ (3,212) Operating loss Á \$ (1,590) Á \$ (2,776) Á \$ 1,186 Á \$ (5,713) Á \$ (8,925) Á \$ 3,212 Á Net loss Á \$ (1,524) Á \$ (2,780) Á \$ 1,256 Á \$ (5,524) Á \$ (8,931) Á \$ 3,407 Á Á Comparison of the Three and Nine Months Ended September 30, 2024 and 2023 Á Operating Expenses Á The following table summarizes our total operating expenses, for the periods indicated, in thousands: Á â€œ Three Months Ended September 30, Á â€œ Nine Months Ended September 30, Á â€œ Description Á 2024 Á 2023 Á Dollar Change Á 2024 Á 2023 Á Dollar Change Research and development Á \$ 644 Á \$ 1,808 Á \$ (1,164) Á \$ 2,658 Á \$ 5,325 Á \$ (2,667) General and administrative Á 946 Á \$ â€œ 968 Á \$ (22) Á \$ 3,055 Á \$ 3,600 Á Á (545) Total operating expenses Á \$ 1,590 Á \$ 2,776 Á \$ (1,186) Á \$ 5,713 Á \$ 8,925 Á \$ (3,212) Á Á Á Research and Development Expenses Á Research and development expenses relate to compensation and benefits for research and development personnel, facility-related expenses, supplies, external services, costs to acquire technology licenses, research activities under our research collaboration agreement, expenses associated with preclinical and clinical development activities and other operating costs. Our research and development programs are focused on the development of immuno-oncology therapeutics based on our INTASYL therapeutic platform. Since we commenced operations, research and development expenses have been a significant portion of our total operating expenses and are expected to constitute the majority of our spending for the foreseeable future. Á Research and development expenses for the three months ended September 30, 2024 decreased 64% as compared with the three months ended September 30, 2023. The decrease in research and development expenses was primarily driven by our cost rationalization measures in transitioning from a research company to a product development company resulting in a decrease of \$286,000 in salary-related costs, including stock-based compensation expense, and \$85,000 due to the wind-down of preclinical studies, and \$835,000 primarily related to our former Clinical Co-Development Agreement from the prior year period. Á Research and development expenses for the nine months ended September 30, 2024 decreased 50% as compared with the nine months ended September 30, 2023. The decrease in research and development expenses was primarily driven by our cost rationalization measures in transitioning from a research company to a product development company resulting in a decrease of \$880,000 of expense due to the wind-down of preclinical studies, \$1,108,000 in salary-related costs, including stock-based compensation expense, and \$204,000 in lab supplies associated with the reduction in headcount, in addition to decreases in clinical consulting fees of \$350,000 incurred in connection with our IND filing for PH-762 in the prior period, decreases in clinical trial-related fees for our former PH-762 trials in ACT and European clinical trial, and a decrease of \$208,000 in manufacturing fees for PH-762. Á We anticipate our research and development expenses will remain relatively consistent for the remainder of 2024. Á General and Administrative Expenses Á General and administrative expenses relate to compensation and benefits for general and administrative personnel, facility-related expenses, professional fees for legal and patent-related activities, audit, tax and consulting services, as well as other general corporate expenses. Á General and administrative expenses for the three months ended September 30, 2024 decreased 2% as compared with the three months ended September 30, 2023. The decrease in general and administrative expenses was primarily due to a decrease in salary-related expenses. Á General and administrative expenses for the nine months ended September 30, 2024 decreased 15% as compared with the nine months ended September 30, 2023. The decrease in general and administrative expenses was primarily due to decreases in salary-related expenses due to reductions in headcount of \$196,000, in professional fees for a total of \$229,000 primarily related to legal and patent expenses, and in our D&O insurance premium of \$74,000 as compared to the prior year period. Á We anticipate our general and administrative expenses will remain relatively consistent for the remainder of 2024. Á Á Á 20A Á Á Liquidity and Capital Resources Á Historically, our primary source of funding has been through the sale of our securities. In the future, we will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity or strategic opportunities, in order to maintain our operations. We have reported recurring losses from operations since inception and expect that we will continue to have negative cash flows from our operations for the foreseeable future. At September 30, 2024, we had cash of \$5,390,000 as compared with \$8,490,000 at December 31, 2023. Á On May 16, 2024, we entered into a purchase agreement (the â€œPurchase Agreementâ€œ) with Triton Funds LP (â€œTritonâ€œ), pursuant to which we agreed to sell, and Triton agreed to purchase, upon our request in one or more transactions, up to 95,833 shares of our common stock at a purchase of \$6.48 per share (the â€œPurchase Priceâ€œ), for aggregate gross proceeds of up to \$621,000. On July 3, 2024, we terminated the Purchase Agreement with Triton effective immediately. No shares of common stock were sold by us pursuant to the Purchase Agreement prior to termination. Á In July 2024, we entered into inducement letter agreements (the â€œJuly 2024 Inducement Letter Agreementsâ€œ) with certain holders of certain of our existing warrants to purchase up to an aggregate of 545,286 shares of the Companyâ€™s common stock. The existing warrants were originally issued in February 2020 through December 2023, having exercise prices between \$324.00 and \$9.72 per share. Pursuant to the July 2024 Inducement Letter Agreements, these warrants were exercised for cash at a reduced exercise of \$5.45 per share in consideration of our agreement to issue new unregistered five and one-half year term Series C warrants to purchase up to 583,098 shares of common stock at an exercise price of \$5.45 and new unregistered eighteen month term Series D warrants to purchase up to 507,474 shares of common stock at an exercise price of \$5.45, both issued and sold at a price of \$0.125 per warrant share (the â€œJuly 2024 Financingâ€œ). The net proceeds to us from the July 2024 Financing were approximately \$2,646,000, after deducting placement agent fees and offering expenses. Á We have limited cash resources, have reported recurring losses from operations since inception, have negative operating cash flows and have not yet received product revenues. These factors raise substantial doubt regarding our ability to continue as a going concern, and our current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of the condensed consolidated financial statements included elsewhere in this Quarterly Report. Our continuation as a going concern depends upon our ability to raise additional capital through equity offerings, debt offerings and/or strategic opportunities to fund our operations. There can be no assurance that we will be successful in accomplishing any of these plans in order to continue as a going concern. The condensed consolidated financial statements included elsewhere in this Quarterly Report do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Á The following table summarizes our cash flows for the periods indicated, in thousands: Á Á Nine Months Ended September 30, Á Á 2024 Á 2023 Net cash used in operating activities Á \$(5,741) Á \$(8,379) Net cash used in investing activities Á â€œ Á Á (5) Net cash provided by financing activities Á 2,641 Á \$ 5,010 Net decrease in cash, cash equivalents and restricted cash Á \$(3,100) Á \$(3,374) Á Á 21A Á Á Net Cash Flow from Operating Activities Á Net cash used in operating activities was \$5,741,000 for the nine months ended September 30, 2024 as compared with \$8,379,000 for the nine months ended September 30, 2023. The decrease was primarily due to a decrease in net loss of \$3,407,000, a decrease in non-cash related items of \$298,000 primarily related to reduced stock-based compensation expense, and a decrease in the changes in operating assets and liabilities of \$472,000 primarily as a result of liabilities owed for the completion of preclinical studies in the prior year period. Á Net Cash Flow from Investing Activities Á There were no investing activities for the nine months ended September 30, 2024 as compared with \$5,000 for the nine months ended September 30, 2023. The decrease in net cash used in investing activities was primarily due to laboratory and computer equipment purchases for our facility during the prior year period. Á Net Cash Flow from Financing Activities Á Net cash provided by financing activities was \$2,641,000 for the nine months ended September 30, 2024 as compared with \$5,010,000 for the nine months ended September 30, 2023. The decrease was primarily due to the net proceeds from the completion of our financing activities during the prior year period as compared with the current year period. Á Contractual Obligations Á Details of our obligations under the Clinical Co-Development Agreement with our former collaboration partner AgonOx can be found in Note 2 of the condensed consolidated financial statements. Outside of the above, there have been no material changes to the contractual obligations as disclosed in our 2023 Form 10-K. Á Future Funding Requirements Á At September 30, 2024, we had cash and cash equivalents of \$5,390,000 and received estimated net proceeds of \$2,646,000 from our July 2024 Financing. We expect that our cash and cash equivalents will enable us to fund our current operating plan into Q2 2025. Due to the difficulty and uncertainty associated with the design and implementation of preclinical studies and clinical trials, we will continue to assess our cash and cash equivalents and future funding requirements. However, there is no assurance that additional funding will be achieved and that we will succeed in our future operations. We expect to continue to incur substantial additional operating losses for at least the next several years as we continue to develop our product candidates and seek marketing approval and, subject to obtaining such approval, the eventual commercialization of our product candidates. If we obtain marketing approval for any of our product candidates, we will incur significant sales, marketing and manufacturing expenses. We also expect to continue to incur significant costs to comply with corporate governance, internal controls and similar requirements associated with operating as a public reporting company. Á Actual cash requirements could differ from managementâ€™s projections due to many factors including additional investments in research and development programs, clinical trial expenses for PH-762, competing technological and market developments, general and administrative expenses, and the costs of any strategic acquisitions and/or development of complementary business opportunities. Á We expect to seek additional funding to sustain our future operations and while we have successfully raised capital in the past, the ability to raise capital in future periods is not assured. We do not know if additional capital will be available when needed or on terms favorable to us or our stockholders. Collaboration, licensing or other agreements may not be available on favorable terms, or at all. If we seek to sell our equity securities, we do not know whether and to what extent we will be able to do so, or on what terms. If available, additional equity financing may be dilutive to stockholders, debt financing may involve restrictive covenants or other unfavorable terms and dilute our existing stockholdersâ€™ equity, and funding through collaboration, licensing or other commercial agreements may be on unfavorable terms, including requiring us to relinquish rights to certain of our technologies or products. If adequate financing is not available if and when needed, we may delay, reduce the scope of, or eliminate research or development programs, if any, postpone or cancel the pursuit of product candidates, or otherwise significantly curtail our operations to reduce our cash requirements and extend our capital. Á Á Á 22A Á Á ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Á As a smaller reporting company, we are not required to provide this information. Á ITEM 4. CONTROLS AND PROCEDURES Á Evaluation of Disclosure Controls and Procedures Á Our management, with the participation of our Principal Executive Officer and our Principal Financial Officer, evaluated the effectiveness of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€œ)) as of the end of the period covered by this report to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized

and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. 5. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, management, with the participation of our Principal Executive Officer and our Principal Financial Officer, concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date. 6. Changes in Internal Control Over Financial Reporting 6.1 There have been no changes in our internal control over financial reporting that occurred during the quarter ending September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 7. OTHER INFORMATION 7.1 LEGAL PROCEEDINGS 7.2 From time to time, we may become a party to various legal proceedings and complaints arising in the ordinary course of business. We are not currently a party to any actual or threatened material legal proceedings of which we are aware. 8. RISK FACTORS 8.1 Other than set forth below, there have been no material changes in our risk factors set forth in Part I, 8.2 Item 1A. Risk Factors 8.3 In our 2023 Form 10-K. The risk factor set forth below and risk factors disclosed in Part I, 8.4 Item 1A. Risk Factors 8.5 In our 2023 Form 10-K could materially adversely affect our business, financial condition, or results of operations. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including these risks. Additional risks not currently known or currently material to us may also harm our business. 9. We may not be able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market. 10. A Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders' equity of at least \$2.5 million for continued listing. As of September 30, 2024, our stockholders' equity was \$4.9 million and there can be no assurance that we will be able to maintain or increase our stockholders' equity in the future. If our stockholders' equity falls below \$2.5 million, as a result of operating losses or for other reasons, or if we are unable to demonstrate to Nasdaq's satisfaction that we subsequently regained compliance with this requirement, Nasdaq will notify us of such non-compliance. If we receive such notice from Nasdaq, in accordance with the Nasdaq Listing Rules, we will have 45 calendar days from the date of the notification to submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1). If our compliance plan is accepted, we may be granted up to 180 calendar days from the date of the initial notification to evidence compliance. If our compliance plan is not accepted or we are otherwise unable to evidence compliance within Nasdaq's allotted timeframe, Nasdaq may take steps to delist our common stock. 11. Such a delisting would have an adverse effect on the market liquidity of our securities, decrease the market price of our securities, result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities, and adversely affect our ability to obtain financing for the continuation of our operations. We are actively monitoring our stockholders' equity and will consider any and all options available to us to maintain compliance with Nasdaq Listing Rule 5550(b)(1). 12. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 13. No sales or issuances of unregistered securities occurred that have not previously been disclosed in a Current Report on Form 8-K. 14. ITEM 3. DEFAULTS UPON SENIOR SECURITIES 15. None. 16. ITEM 4. MINE SAFETY DISCLOSURES 17. Not applicable. 18. 24A ITEM 5. OTHER INFORMATION 19. During the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K. 20. ITEM 6. EXHIBITS 21. EXHIBIT INDEX 22. Incorporated by Reference Herein Exhibit Number 1 Description Form 4 Date 23. 3.1 Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. 24. Current Report on Form 8-K (File No. 001-36304) 25. November 19, 2018 26. 3.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. 27. Current Report on Form 8-K (File No. 001-36304) 28. January 14, 2020 29. 3.3 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. 30. Current Report on Form 8-K (File No. 001-36304) 31. January 25, 2023 32. 3.4 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. 33. Current Report on Form 8-K (File No. 001-36304) 34. July 2, 2024 35. 3.5 Amended and Restated Bylaws of Phio Pharmaceuticals Corp. 36. Current Report on Form 8-K (File No. 001-36304) 37. May 2, 2022 38. 4.1 Form of Series C/D Warrant, dated July 12, 2024. 39. Current Report on Form 8-K (File No. 001-36304) 40. July 12, 2024 41. 4.2 Form of Placement Agent Warrant, dated July 12, 2024. 42. Current Report on Form 8-K (File No. 001-36304) 43. July 12, 2024 44. 10.1 Form of Inducement Letter Agreement, dated July 12, 2024, by and between Phio Pharmaceuticals Corp. and the Holders. 45. Current Report on Form 8-K (File No. 001-36304) 46. July 12, 2024 47. 10.2 Offer Letter, executed July 16, 2024, by and between the Company and Robert M. Infarinato. 48. Current Report on Form 8-K (File No. 001-36304) 49. August 1, 2024 50. 11.1 Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer. 51. 52. 3.1.2 Sarbanes-Oxley Act Section 302 Certification of Principal Financial Officer. 53. 54. 3.1.1 Sarbanes-Oxley Act Section 906 Certification of Principal Executive Officer. 55. 56. 3.1.2 Sarbanes-Oxley Act Section 906 Certification of Principal Financial Officer. 57. 58. 101.INS Inline XBRL Instance Document. 59. 60. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 61. 62. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 63. 64. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 65. 66. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 67. 68. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 69. 70. 104 The cover page for this report, formatted in Inline XBRL (included in Exhibit 101). 71. 72. Filed herewith. 73. Furnished herewith and not deemed filed for purposes of Section 13 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act. 74. 25A SIGNATURES 75. Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 76. 77. By: /s/ Robert J. Bitterman 78. 79. Robert J. Bitterman 80. President and Chief Executive Officer (as Principal Executive Officer) 81. 82. Date: November 14, 2024 83. By: /s/ Robert M. Infarinato 84. 85. Robert M. Infarinato 86. Vice President, Chief Financial Officer (as Principal Financial Officer) 87. 88. Date: November 14, 2024 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. EX-31.1 2 phio ex3101.htm CERTIFICATION Exhibit 31.1 A CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULES 13a-14(a) AND 15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 101. I, Robert J. Bitterman, certify that: 102. 1. I have reviewed this Quarterly Report on Form 10-Q of Phio Pharmaceuticals Corp.; 103. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 104. 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 105. 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 106. a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; 107. b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 108. c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 109. d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 110. 5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): 111. a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and 112. b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting. 113. Dated: November 14, 2024 114. /s/ Robert J. Bitterman 115. Robert J. Bitterman 116. President and Chief Executive Officer (as Principal Executive Officer) 117. EX-31.2 3 phio ex3102.htm CERTIFICATION Exhibit 31.2 A CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULES 13a-14(a) AND 15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 118. I, Robert M. Infarinato, certify that: 119. 1. I have reviewed this Quarterly Report on Form 10-Q of Phio Pharmaceuticals Corp.; 120. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 121. 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 122. 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 123. a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; 124. b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 125. c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 126. d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 127. 5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): 128. a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and 129. b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting. 130. Dated: November 14, 2024 131. /s/ Robert M. Infarinato 132. Robert M. Infarinato 133. Vice President, Chief Financial Officer (as Principal Financial Officer) 134. EX-32.1 4 phio ex3201.htm CERTIFICATION Exhibit 32.1 A CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 135. In connection with the Quarterly Report of Phio Pharmaceuticals Corp. (the "Company") on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 20

101.DEF 8 phio-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 phio-20240930_lab.xml XBRL LABEL FILE Equity Components [Axis] Preferred Stock Series D [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Transaction Type [Axis] Clinical Co Development Agreement [Member] Counterparty Name [Axis] Agon Ox [Member] Asset Class [Axis] Cash and Cash Equivalents [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Property Subject to or Available for Operating Lease [Axis] Property Subject to Operating Lease [Member] Long-Lived Tangible Asset [Axis] Laboratory Facility [Member] Securities Financing Transaction [Axis] May 2024 Financing [Member] July 2024 Financing [Member] Class of Stock [Axis] Series C Warrants [Member] Series D Warrants [Member] Equity Classified Warrants [Member] Placement Agent Warrants [Member] July 2024 Abeyance Shares [Member] July 2024 Inducement Letter Agreement [Member] April 2023 Financing [Member] Series A Warrants [Member] Series B Warrants [Member] Warrant Amendment Agreements [Member] Award Type [Axis] Previously Issued Warrants [Member] June 2023 Financing [Member] Registered Shares [Member] Unregistered Shares [Member] Unregistered Pre Funded Warrants [Member] Stock Conversion Description [Axis] June 2023 Prefunded Warrants [Member] Warrant [Member] Restricted Stock Units (RSUs) [Member] Employees [Member] Share-Based Payment Arrangement, Option [Member] Non Employee Members [Member] Statement of Income Location, Balance [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Antidilutive Securities [Axis] Stock Options [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Prepaid expenses and other current assets Total current assets Right of use asset Property and equipment, net Other assets Total assets LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Current liabilities: Accounts payable Accrued expenses Lease liability Total current liabilities Commitments and contingencies (Note 2) Stockholdersâ€™ equity: Preferred stock, \$0.0001 par value, 100,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Common stock, \$0.0001 par value, 100,000,000 shares authorized; 958,219 and 416,368 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Additional paid-in capital Accumulated deficit Total stockholdersâ€™ equity Total liabilities and stockholdersâ€™ equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Total operating expenses Operating loss Total other income (expense), net Net loss Net loss per common share: Net loss per common share, Basic Net loss per common share, Diluted Weighted average number of common shares outstanding Weighted average number of common shares outstanding, Basic Weighted average number of common shares outstanding, Diluted Statement [Table] Statement [Line Items] Beginning balance, value Balance at beginning, shares Cash-in-lieu of fractional shares for reverse stock split Cash-in-lieu of fractional shares for reverse stock split, shares Issuance of common stock and warrants, net of offering costs Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of warrants, shares Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon vesting of restricted stock units, shares Shares withheld for payroll taxes Shares withheld for payroll taxes, shares Stock-based compensation expense Net loss [custom:StockAndWarrantsIssuedDuringPeriodValueNewIssues] Issuance of common stock and warrants, net of offering costs, shares Cash-in-lieu of fractional shares for reverse stock split [custom:StockAndWarrantsIssuedDuringPeriodSharesNewIssues] Redemption of preferred stock [custom:RedemptionOfPreferredStock] Redemption of preferred stock, shares Ending balance, value Balance at ending, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Amortization of right of use asset Loss on disposal of property and equipment Stock-based compensation Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued expenses Lease liability Net cash used in operating activities Cash flows from investing activities: Cash paid for purchase of property and equipment Net cash used in investing activities Cash flows from financing activities: Net proceeds from the issuance of common stock and warrants Cash in lieu of fractional shares for reverse stock split Redemption of Series D preferred stock Payment of taxes on net share settlements of restricted stock units Net cash provided by financing activities Net decrease in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at the beginning of period Cash, cash equivalents and restricted cash at the end of period Restricted cash Cash, cash equivalents and restricted cash Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment to PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Accounting Policies [Abstract] Organization and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaboration Agreement Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Leases Leases Equity [Abstract] Stockholdersâ€™ Equity Share-Based Payment Arrangement [Abstract] Stock-based Compensation Earnings Per Share [Abstract] Net Loss per Common Share Subsequent Events [Abstract] Subsequent Events Nature of Operations Basis of Presentation Principles of Consolidation Segments Use of Estimates Liquidity Summary of Significant Accounting Policies Recent Accounting Pronouncements Schedule of financial instruments at fair value Schedule of lease amounts recorded in balance sheet Schedule of outstanding warrants Summary of RSUs activity Summary of stock options activity Schedule of stock-based compensation expense Schedule of anti dilutive shares Reverse stock split Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Contractual obligation [custom:ExpenseFromContractualObligations] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Total Assets Liabilities Lease liability Lease Term and Discount Rate Weighted average remaining lease term Weighted average discount rate Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Operating lease footage Lease expiration date Total base rent Operating lease expense Operating lease costs Operating Lease, Payments Stock, Class of Stock [Table] Class of Stock [Line Items] Warrants outstanding, Beginning balance Warrants outstanding weighted average exercise price per share, Beginning balance Warrants issued, shares Warrants issued weighted average exercise price per share Warrants exercised, shares Warrants exercised weighted average exercise price per share Warrants expired, shares Warrants expired weighted average exercise price per share Warrants outstanding, Ending balance Warrants outstanding weighted average exercise price per share, Ending balance Common stock shares Purchase price Gross proceeds from common stock Non-cash equity issuance cost Shares of common stock held in abeyance Abeyance shares issued Number of shares issued Warrant new shares issued Exercise price Proceeds from equity Amended warrants Proceeds from amendment of warrants Increase in fair value of warrants Shares of common stock issued related to exercise of pre-funded warrants Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of invested restricted stock units, Beginning balance Weighted- average grant date fair value per share of unvested restricted stock units, Beginning balance Number of restricted stock units, Granted and accepted Weighted- average grant date fair value per share of restricted stock units, Granted and accepted Number of restricted stock units, Vested Weighted- average grant date fair value per share of restricted stock units, Vested Number of restricted stock units, Forfeited Weighted- average grant date fair value per share of restricted stock units, Forfeited Number of unvested restricted stock units, Ending balance Weighted- average grant date fair value per share of unvested restricted stock units, Ending balance Options outstanding, beginning balance Options outstanding, price per share, beginning balance Options granted Options granted, price per share Options exercised Options exercised, price per share Options forfeited Options forfeited, price per share Options expired Options expired, price per share Options outstanding, ending balance Options outstanding, price per share, ending balance Aggregate intrinsic value, outstanding Options exercisable Options exercisable, price per share Aggregate intrinsic value, exercisable Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock-based compensation Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based compensation expense Fair value of awards vested Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive shares Assets, Current Assets [Default Label] Liabilities, Current Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Shares, Outstanding Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Stock Redeemed or Called During Period, Value Stock Redeemed or Called During Period, Shares Gain (Loss) on Disposition of Property Plant Equipment Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Operating Lease Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities CashInLieuOfFractionalSharesForReverseStockSplit Payments for Repurchase of Redeemable Preferred Stock Payment, Tax Withholding, Share-Based Payment Arrangement Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Lessee, Operating Leases [Text Block] Operating Lease, Liability Class of Warrant or Right, Outstanding ClassOfWarrantOrRightWeightedAverageExercisePrice Warrants Exercised Share WarrantsExpiredShares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period EX-101.PRE 10 phio-20240930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 14, 2024 Cover [Abstract] A A Document Type 10-Q A Amendment Flag false A Document Quarterly Report true A Document Transition Report false A Document Period End Date Sep. 30, 2024 A Document Fiscal Period Focus Q3 A Document Fiscal Year Focus 2024 A Current Fiscal Year End Date -12-31 A Entity File Number 001-36304 A Entity Registrant Name Phio Pharmaceuticals Corp. A Entity Central Index Key 0001533040 A Entity Tax Identification Number 45-3219903 A Entity Incorporation, State or Country Code DE A Entity Address, Address Line One 11 Apex Drive A Entity Address, Address Line Two Suite 300A, PMB 2006 A Entity Address, City or Town Marlborough A Entity Address, State or Province MA A Entity Address, Postal Zip Code 01752 A City Area Code 508 A Local Phone Number 767-3861 A Title of 12(b) Security Common Stock par value, \$0.0001 per share A Trading Symbol PHIO A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 1,055,219 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:yearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition

available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405> + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b> + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1> + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: A Cash and cash equivalents \$ 5,390 \$ 8,490 Prepaid expenses and other current assets 474 832 Total current assets 5,864 9,322 Right of use asset 0 33 Property and equipment, net 1 6 Other assets 0 3 Total assets 5,865 9,364 Current liabilities: A Accounts payable 184 657 Accrued expenses 735 942 Lease liability 0 35 Total current liabilities 919 1,634 Commitments and contingencies (Note 2) Stockholdersâ€™ equity: A Preferred stock, 0.0001 par value, 100,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 0 0 Common stock, 0.0001 par value, 100,000,000 shares authorized; 958,219 and 416,368 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 0 0 Additional paid-in capital 149,676 146,936 Accumulated deficit (144,730) (139,206) Total stockholdersâ€™ equity 4,946 7,730 Total liabilities and stockholdersâ€™ equity \$ 5,865 \$ 9,364 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2>: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2>: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(18\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapital Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2>: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5): [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6): <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9): [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10): [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11): [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12): <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13>: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(vi\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(vi)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22): <http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29](http://www.xbrl.org/2003/role/disclosureRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29): [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1) + Details Name: us-gaap Assets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6): <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-01\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-01(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-01\(a\)\(4\)\(vi\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-01(a)(4)(vi)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-01\(a\)\(4\)\(vii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-01(a)(4)(vii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12):

Paragraph 1 - Subparagraph (SX 210.5-02(9)) - Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 -Details Name: us-gaap AssetsCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 -Details Name: us-gaap AssetsCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1): [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2): [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3): [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 -Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into \(1\) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and \(2\) is exposed to potential losses or, less frequently, gains, arising from \(a\) possible claims against a company's resources due to future performance under contract terms, and \(b\) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 -Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3): [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 -Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock \(or common stock redeemable solely at the option of the issuer\). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 -Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2): <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 -Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 -Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1): <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(32\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 -Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disc](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4): [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5): <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8):

page 52 - Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-50-52Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1

DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) - USD (\$\$) \$ in Thousands Preferred Stock Series D [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Beginning balance, value at Dec. 31, 2022 \$ 2 \$ 139,218 \$ (128,380) \$ 10,838 Balance at beginning, shares at Dec. 31, 2022 1 126,558 \$ \$ Cash-in-lieu of fractional shares for reverse stock split 11 11 Cash-in-lieu of fractional shares for reverse stock split, shares \$ (190) \$ \$ Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon vesting of restricted stock units, shares \$ 2,009 \$ \$ Shares withheld for payroll taxes (25) (25) Shares withheld for payroll taxes, shares \$ (535) \$ \$ Stock-based compensation expense 111 111 Net loss (3,602) (3,602) Cash-in-lieu of fractional shares for reverse stock split (11) (11) Redemption of preferred stock \$ (2) Redemption of preferred stock, shares (1) \$ \$ Ending balance, value at Mar. 31, 2023 139,293 (131,982) 7,311 Balance at ending, shares at Mar. 31, 2023 0 127,842 \$ \$ Beginning balance, value at Dec. 31, 2022 \$ 2 139,218 (128,380) 10,838 Balance at beginning, shares at Dec. 31, 2022 1 126,558 \$ \$ Net loss \$ (8,931) Ending balance, value at Sep. 30, 2023 144,524 (137,311) 7,213 Balance at ending, shares at Sep. 30, 2023 0 256,375 \$ \$ Beginning balance, value at Mar. 31, 2023 139,293 (131,982) 7,311 Balance at beginning, shares at Mar. 31, 2023 0 127,842 \$ \$ Issuance of common stock and warrants, net of offering costs 5,048 5,048 Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of warrants, shares \$ 19,444 \$ \$ Stock-based compensation expense 94 94 Net loss (2,549) (2,549) Issuance of common stock and warrants, net of offering costs, shares \$ 73,292 \$ \$ Ending balance, value at Jun. 30, 2023 144,435 (134,531) 9,904 Balance at ending, shares at Jun. 30, 2023 0 220,578 \$ \$ Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of warrants, shares \$ 35,588 \$ \$ Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon vesting of restricted stock units, shares \$ 222 \$ \$ Shares withheld for payroll taxes Shares withheld for payroll taxes, shares \$ (13) \$ \$ Stock-based compensation expense 89 89 Net loss (2,780) (2,780) Ending balance, value at Sep. 30, 2023 144,524 (137,311) 7,213 Balance at ending, shares at Sep. 30, 2023 0 256,375 \$ \$ Beginning balance, value at Dec. 31, 2023 146,936 (139,206) 7,730 Balance at beginning, shares at Dec. 31, 2023 0 416,368 \$ \$ Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of warrants, shares \$ 91,820 \$ \$ Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon vesting of restricted stock units, shares \$ 2,689 \$ \$ Shares withheld for payroll taxes (4) (4) Shares withheld for payroll taxes, shares \$ (689) \$ \$ Stock-based compensation expense 32 32 Net loss (2,154) (2,154) Ending balance, value at Mar. 31, 2024 146,964 (141,360) 5,604 Balance at ending, shares at Mar. 31, 2024 0 510,188 \$ \$ Beginning balance, value at Dec. 31, 2023 146,936 (139,206) 7,730 Balance at beginning, shares at Dec. 31, 2023 0 416,368 \$ \$ Net loss \$ (5,524) Ending balance, value at Sep. 30, 2024 149,676 (144,730) 4,946 Balance at ending, shares at Sep. 30, 2024 0 958,219 \$ \$ Beginning balance, value at Mar. 31, 2024 146,964 (141,360) 5,604 Balance at beginning, shares at Mar. 31, 2024 0 510,188 \$ \$ Stock-based compensation expense 15 15 Net loss (1,846) (1,846) Ending balance, value at Jun. 30, 2024 146,979 (143,206) 3,773 Balance at ending, shares at Jun. 30, 2024 0 510,188 \$ \$ Cash-in-lieu of fractional shares for reverse stock split (1) (1) Cash-in-lieu of fractional shares for reverse stock split, shares \$ (255) \$ \$ Issuance of common stock and warrants, net of offering costs 2,646 2,646 Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of warrants, shares \$ 231,758 \$ \$ Stock-based compensation expense 52 52 Net loss (1,524) (1,524) Issuance of common stock and warrants, net of offering costs, shares \$ 149,676 \$ (144,730) \$ 4,946 Balance at ending, shares at Sep. 30, 2024 0 958,219 \$ \$ X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12> + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalStockSplit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrli.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrli.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrli.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrli.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrli.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrli.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrli.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 28: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 29: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 30: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 31: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 32: [http://www.xbrli.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrli.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 36: [http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap SharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 8:

gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2> + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478009/946-205-45-4>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478009/946-205-45-4>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2> + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2> + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 17 R6.htm XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: A A Net loss \$ (5,524) \$ (8,931) Adjustments to reconcile net loss to net cash used in operating activities: A A Depreciation and amortization 2 46 Amortization of right of use asset 33 95 Loss on disposal of property and equipment 3 0 Stock-based compensation 99 294 Changes in operating assets and liabilities: A A Prepaid expenses and other assets 361 (235) Accounts payable (473) (606) Accrued expenses (207) 1,058 Lease liability (35) (100) Net cash used in operating activities (5,741) (8,379) Cash flows from investing activities: A A Cash paid for purchase of property and equipment 0 (5) Net cash used in investing activities 0 (5) Cash flows from financing activities: A A Net proceeds from the issuance of common stock and warrants 2,646 5,048 Cash in lieu of fractional shares for reverse stock split (1) (11) Redemption of Series D preferred stock 0 (2) Payment of taxes on net share settlements of restricted stock units (4) (25) Net cash provided by financing activities 2,641 5,010 Net decrease in cash, cash equivalents and restricted cash (3,100) (3,374) Cash, cash equivalents and restricted cash at the beginning of period 8,490 11,831 Cash, cash equivalents and restricted cash at the end of period \$ 5,390 \$ 8,457 X - ReferencesNo definition available. + Details Name: phio_CashInLieuOfFractionalSharesForReverseStockSplit Namespace Prefix: phio_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22> + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type

Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1:

S99-1Reference 7:

AgonOx are coordinating the orderly wind-down of the Phase 1 clinical trial. Each of the Company and AgonOx shall be responsible for its own costs and expenses incurred in connection with the wind-down of the Phase 1 clinical trial. Â The Company recognized approximately \$308,000 and \$414,000 in connection with the Clinical Co-Development Agreement during the three and nine months ended September 30, 2024, respectively, which relate to the Companyâ€™s expense obligations under the Clinical Co-Development Agreement through the date of termination. The Company recognized approximately \$606,000 and \$906,000 of expense in connection with the Clinical Co-Development Agreement during the three and nine months ended September 30, 2023, respectively. Â X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 802 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 802 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value of Financial Instruments 3.Â Fair Value of Financial Instruments Â The Company follows the provisions of the FASB Accounting Standards Codification (â€œASCâ€) Topic 820, â€œFair Value Measurement,â€ for the Companyâ€™s financial assets and liabilities that are re-measured and reported at fair value each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows: Â Level 1 â€ quoted prices in active markets for identical assets or liabilities. Â Level 2 â€ other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Â Level 3 â€ significant unobservable inputs that reflect managementâ€™s best estimate of what market participants would use to price the assets or liabilities at the measurement date. Â As of September 30, 2024, the Company categorized its cash equivalents as Level 1 hierarchy as the carrying amounts approximate their fair value due to their short-term nature and market rates of interest. As of December 31, 2023, the Company did not identify any financial instruments required to be presented at fair value. Schedule of financial instruments at fair valueÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â DescriptionÂ September 30, 2024Â Quoted Prices In Active Markets (Levelâ€ 1)Â Â â€ Other Significant Observable Inputs (Levelâ€ 2)Â Unobservable Inputs (Levelâ€ 3) Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalentsÂ $5,390.Â Â $5,390.Â Â $â€Â Â Â $â€Â Â Â TotalÂ $5,390.Â Â $5,390.Â Â $â€Â Â Â $â€Â Â Â The carrying amounts of cash, accounts payable and accrued expenses of the Company approximate their fair values due to their short-term nature. Â X - ReferencesNo definition available. + Details Name: us-gaap FairValueDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 12:

ownership limitations and were exercised pursuant to a notice of exercise from the holder. Until such time, the December 2023 Abeyance Shares were evidenced through the holder’s existing warrants and have been included in the Company’s table of outstanding warrants below. A Pursuant to the terms of the Inducement Letter Agreement, in the event that the exercise of the existing warrants in the December 2023 Financing would have otherwise caused a holder to exceed the beneficial ownership limitations set forth in the existing warrant, the Company issued the number of shares that would not cause a holder to exceed such beneficial ownership limitation and agreed to hold such balance of shares of common stock in abeyance. Accordingly, at December 31, 2023, an aggregate of 91,819.4 shares of common stock were held in abeyance (the “Abeyance Shares”) with such Abeyance Shares evidenced through the holder’s existing warrants and which are deemed to be prepaid. The Abeyance Shares will be held until notice is received by the holder that the balance of the shares of common stock may be issued in compliance with such beneficial ownership limitations and may be exercised pursuant to a notice of exercise from the holder. Until such time, the Abeyance Shares are evidenced through the holder’s existing warrants and have been included in the Company’s table of outstanding warrants below. The remainder of the December 2023 Abeyance Shares were subsequently released during the first quarter of 2024. A Warrants A The Company first assesses warrants that are issued by the Company under the FASB ASC Topic 480, “Distinguishing Liabilities from Equity” (ASC 480) to determine whether the warrants are within the scope of ASC 480. If there are no instances outside of the Company’s control that could require cash settlement, the Company then applies and follows the applicable accounting guidance in ASC 815. Financial instruments are accounted for as either derivative liabilities or equity instruments depending on the specific terms of the agreement. Based on the assessment of the warrants issued by the Company under the guidance in ASC 480 and ASC 815, the warrants issued by the Company have been classified within stockholder’s equity. A During the three months ended September 30, 2024, 231,758 of the July 2024 Abeyance Shares were released and issued. During the three months ended September 30, 2023, 35,588 shares of common stock were issued related to the exercise of pre-funded warrants from the June 2023 Financing. A During the nine months ended September 30, 2024, all of the December 2023 Abeyance Shares were released and issued and 231,758 of the July 2024 Abeyance Shares were released and issued. During the nine months ended September 30, 2023, 55,032 shares of common stock were issued related to the exercise of pre-funded warrants from the June 2023 Financing. A The following table summarizes the Company’s outstanding warrants, all of which are classified as equity instruments, at September 30, 2024: Schedule of outstanding warrants A A A A Number of SharesA Weighted- Average Exercise Price Per Share Outstanding at December 31, 2023A A 703,530.4 A \$35.99A IssuedA A 1,131,468.4 A A 5.50A ExercisedA A (540,112.4) A A 6.56A ExpiredA A A A A Outstanding at September 30, 2024A A 1,294,886.4 A \$21.62A A X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1:

â€œCompanyâ€ is a clinical stage biotechnology company whose proprietary INTASYLÂ® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the bodyâ€™s ability to fight cancer, without the need for specialized formulations or drug delivery systems. A Phio was incorporated in the state of Delaware in 2011 as RXi Pharmaceuticals Corporation. On November 19, 2018, the Company changed its name to Phio Pharmaceuticals Corp., to reflect its transition from a platform company to one that is fully committed to developing groundbreaking immuno-oncology therapeutics. A Effective July 5, 2024, the Company completed a 1-for-9 reverse stock split of the Companyâ€™s outstanding common stock, including reclassifying an amount equal to the reduction in par value to additional paid-in capital. The reverse stock split did not reduce the number of authorized shares of the Companyâ€™s common or preferred stock. All share and per share amounts have been adjusted to give effect to the reverse stock split. A Basis of Presentation Basis of Presentation A The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€). Certain information and footnote disclosures that are included in the Companyâ€™s annual consolidated financial statements, but that are not required for interim reporting purposes, have been condensed or omitted. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. A These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Companyâ€™s most recent Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the â€œSECâ€) on April 1, 2024 (the â€œ2023 Form 10-Kâ€). Interim results are not necessarily indicative of results for a full year. A Principles of Consolidation Principles of Consolidation A The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation. A Segments Segments A The Company operates as a one operating segment and all assets are located in the United States. A Use of Estimates Use of Estimates A The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, and the valuation allowance on the Companyâ€™s deferred tax assets. On an ongoing basis the Company evaluates its estimates and bases its estimates on historical experience and other relevant assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from these estimates. A Liquidity Liquidity A The Company has reported recurring losses from operations since its inception and expects to continue to have negative cash flows from operations for the foreseeable future. Historically, the Companyâ€™s primary source of funding has been from sales of its securities. The Companyâ€™s ability to continue to fund its operations is dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain its operations. This is dependent on a number of factors, including the market demand or liquidity of the Companyâ€™s common stock. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back or terminate its operations or seek to merge with or to be acquired by another company. A The Company has limited cash resources, has reported recurring losses from operations since inception, has negative operating cash flows and has not yet received product revenues. These factors raise substantial doubt regarding the Companyâ€™s ability to continue as a going concern, and the Companyâ€™s current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of these condensed consolidated financial statements. The continuation of the Company as a going concern depends upon the Companyâ€™s ability to raise additional capital through an equity offering, debt offering and/or strategic opportunity to fund its operations. There can be no assurance that the Company will be successful in accomplishing these plans in order to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. A Summary of Significant Accounting Policies Summary of Significant Accounting Policies A Cash and Cash Equivalents A Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase. A Other than as set forth above, there have been no material changes to the significant accounting policies disclosed in the Companyâ€™s 2023 Form 10-K. A Recent Accounting Pronouncements Recent Accounting Pronouncements A In November 2023, the Financial Accounting Standards Board (the â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-07, â€œSegment Reporting (Topic 280) â€” Improvements to Reporting Segment Disclosuresâ€ (â€œASU 2023-07â€), which requires disclosure of incremental segment information on an annual and interim basis. In addition, ASU 2023-07 clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced disclosures are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements and disclosures, but does not expect that it will have a material impact on its consolidated financial statements. A In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740) â€” Improvements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€), which requires disclosure of specific categories in the rate reconciliation table along with additional information for reconciling items that meet a quantitative threshold, disclosure of disaggregated income taxes paid and modifies other income tax-related disclosures. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-09, but does not expect that it will have a material impact on its consolidated financial statements. A X - ReferencesNo definition available. + Details Name: phio_LiquidityPolicyTextBlock Namespace Prefix: phio_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] A Schedule of financial instruments at fair value Schedule of financial instruments at fair value A A A A A A A A A A A A A A A A A A Description A September 30, 2024 A Quoted Prices In Active Markets (Levelâ€ 1) A â€Other Significant Observable Inputs (Levelâ€ 2) A Unobservable Inputs (Levelâ€ 3) A Assets A A A A A A A A A A A A A A A A A A Cash equivalents \$ 5,390.0 A \$ 5,390.0 A \$â€A A Total A \$ 5,390.0 A \$ 5,390.0 A \$â€A A X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases A Schedule of lease amounts recorded in balance sheet Schedule of lease amounts recorded in balance sheet A A A A A A A A September 30, 2024 A December 31, 2023 Assets A A A A A A A A Right of use asset A \$ â€A A \$ 33 A Liabilities A A A A A A A A Lease liability A \$ â€A A \$ 35 A Lease Term and Discount Rate A A A A A A A A Weighted average remaining lease term A A â€A A A 0.25 A Weighted average discount rate A A â€A A A 4.70% A X - ReferencesNo definition available. + Details Name: phio_DisclosureLeasesAbstract Namespace Prefix: phio_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: phio_SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock Namespace Prefix: phio_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] A Schedule of outstanding warrants Schedule of outstanding warrants A A A A A A Number of Shares A Weighted- Average Exercise Price Perâ€ Share Outstanding at Decemberâ€ 31, 2023 A 703,530 A \$ 35.99 A Issued A 1,131,468 A A 5.50 A Exercised A (540,112) A A 6.56 A Expired A â€A A A â€A Outstanding at September 30, 2024 A 1,294,886 A \$ 21.62 A X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights

standing, the aggregate amount of securities sold by or for warrants and rights not existing, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1) + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] A Summary of RSUs activity Summary of RSUs activity A A A A Number of SharesA Weighted-Average Grant Date Fair Value PerA Share Unvested units at DecemberA 31, 2023A A 5,527A A \$74.83A Granted and acceptedA A 71,000A A 2.77A VestedA A (3,997)A A 71.10A ForfeitedA A (1,530)A A 84.55A Unvested units at September 30, 2024A A 71,000A A 2.77A Summary of stock options activity Summary of stock options activity A A A A Number of SharesA Weighted-Average Exercise Price Per ShareA Aggregate Intrinsic Value Balance at December 31, 2023A A 1,146A A \$10,120.69A A A A GrantedA A A A A A A A ExercisedA A A A A A A A ForfeitedA A A A A A A A ExpiredA A (13)A A 598,313.35A A A A Balance at September 30, 2024A A 1,133A A \$3,371.79A A A A A A Exercisable at September 30, 2024A A 1,133A A \$3,371.79A A A A A A Schedule of stock-based compensation expense Schedule of stock-based compensation expenseA A A A A A A A Three Months EndedA Nine Months Ended A A A September 30, A September 30, A A A 2024A 2023A 2024A 2023 Research and developmentA \$25A A \$51A A \$14A A \$163A General and administrativeA A 27A A A 38A A A 85A A A 131A Total stock-based compensationA \$52A A \$89A A \$99A A \$294A X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(h\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Common Share (Tables) 9 Months Ended Sep. 30, 2024 Net loss per common share: A Schedule of anti dilutive shares Schedule of anti dilutive shares A A A A September 30, A A 2024 2023 Stock options A A 1,133 A A 14 A Unvested RSUs A A 71,000 A A 7,694 A Warrants1,2 A A 1,197,886 A A 357,481 A Total A A 1,270,019 A A A 365,189 A A 1 The weighted average number of common shares outstanding as of September 30, 2023 includes pre-funded warrants issued in the June 2023 Financing because the exercise of such warrants requires only nominal consideration. Therefore, these pre-funded warrants are not included in the table above. A 2 The weighted average number of common shares outstanding as of September 30, 2024 includes the Abeyance Shares from the July 2024 Financing, the exercise of which was prepaid and requires no further consideration for the delivery of the shares of common stock. Therefore, 97,000 of these Abeyance Shares are not included in the table above. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Significant Accounting Policies (Details Narrative) Jul. 05, 2024 Accounting Policies [Abstract] A Reverse stock split 1-for-9 reverse stock split X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph \(SAB Topic 4.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4) + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborator Agreement (Details Narrative) - Clinical Co Development Agreement [Member] - Agon Ox [Member] - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A Contractual obligation \$ 4,000,000 A \$ 4,000,000 A [custom:ExpenseFromContractualObligations] \$ 308,000 \$ 606,000 \$ 414,000 \$ 906,000 X - ReferencesNo definition available. + Details Name: phio_ExpenseFromContractualObligations Namespace Prefix: phio Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1) + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3> + Details Name: us-gaap_ContractualObligation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_TransactionTypeAxis=phio_ClinicalCoDevelopmentAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=phio_AgonOxMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - (Details - Financial instruments at fair value) \$ in Thousands Sep. 30, 2024 USD (\$) Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Total \$ 5,390 Fair Value, Inputs, Level 1 [Member] A Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Total 5,390 Fair Value, Inputs, Level 2 [Member] A Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Total 0 Cash and Cash Equivalents [Member] A Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Total 5,390 Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member] A Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Total 5,390 Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member] A Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Total 0 Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member] A Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Total 0 X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members

[https://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 74 -Publisher FASB -URI](https://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 74 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4)

<https://asc.fasb.org/1943274/2147479041/842-20-45-4> + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash payments to lessor's for use of assets under operating leases. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(g\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25) + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A) + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertySubjectToOperatingLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=phio_LaboratoryFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R29.htm IDEA: XBRL DOCUMENT V3.24.3 Stockholders' Equity (Details - Warrants outstanding) - Warrant [Member] 9 Months Ended Sep. 30, 2024 \$ / shares shares Class of Stock [Line Items] A Warrants outstanding, Beginning balance | shares 703,530 Warrants outstanding weighted average exercise price per share, Beginning balance | \$ / shares \$ 35.99 Warrants issued, shares | shares 1,131,468 Warrants issued weighted average exercise price per share | \$ / shares \$ 5.50 Warrants exercised, shares | shares (540,112) Warrants exercised weighted average exercise price per share | \$ / shares \$ 6.56 Warrants expired, shares | shares 0 Warrants expired weighted average exercise price per share | \$ / shares \$ 0 Warrants outstanding, Ending balance | shares 1,294,886 Warrants outstanding weighted average exercise price per share, Ending balance | \$ / shares \$ 21.62 X - ReferencesNo definition available. + Details Name:

phio_ClassOfWarrantOrRightWeightedAverageExercisePrice Namespace Prefix: phio_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: phio_WarrantsExercisedShare Namespace Prefix: phio_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: phio_WarrantsExpiredShares Namespace Prefix: phio_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: phio_WarrantsExpiredWeightedAverageExercisePricePerShare Namespace Prefix: phio_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: phio_WarrantIssuedShares Namespace Prefix: phio_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: phio_WarrantsIssuedWeightedAverageExercisePricePerShare Namespace Prefix: phio_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available.

information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/exampleRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 11: [http://www.xbrl](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

gaap CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAmount of increase (decrease) in equity for freestanding written call option classified as equity from modification recognized as equity issuance cost. Includes, but is not limited to, exchange by issuer and holder. Excludes share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 35 -Paragraph 17 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480299/815-40-35-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 35 -Paragraph 17 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480299/815-40-35-17)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6) + Details Name: us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3) + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2> + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_ConversionOfStockByUniqueDescriptionAxis=phio_June2023PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TransactionTypeAxis=phio_EquityClassifiedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TransactionTypeAxis=phio_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=phio_May2024FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=phio_July2024FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phio_SeriesCWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phio_SeriesDWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=phio_July2024AbeancySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TransactionTypeAxis=phio_July2024InducementLetterAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=phio_April2023FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TransactionTypeAxis=phio_WarrantAmendmentAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=phio_PreviouslyIssuedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phio_SeriesAWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phio_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phio_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=phio_June2023FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phio_RegisteredSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phio_UnregisteredSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phio_UnregisteredPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based Compensation (Details - RSU activity) - Restricted Stock Units (RSUs) [Member] 9 Months Ended Sep. 30, 2024 \$ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A Number of unvested restricted stock units, Beginning balance | shares 5,527 Weighted- average grant date fair value per share of unvested restricted stock units, Beginning balance | \$ / shares 74.83 Number of restricted stock units, Granted and accepted | shares 71,000 Weighted- average grant date fair value per share of restricted stock units, Granted and accepted | \$ / shares 2.77 Number of restricted stock units, Vested | shares (3,997) Weighted- average grant date fair value per share of restricted stock units, Vested | \$ / shares 71.10 Number of restricted stock units, Forfeited | shares (1,530) Weighted- average grant date fair value per share of restricted stock units, Forfeited | \$ / shares 84.55 Number of unvested restricted stock units, Ending balance | shares 71,000 Weighted- average grant date fair value per share of unvested restricted stock units, Ending balance | \$ / shares 2.77 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(vi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(vi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(vii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(vii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(viii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(viii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ix\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ix) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(x\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(x) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xiii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

Topic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv)(01) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11:

us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-
types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of
vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -
SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type:
debit Period Type: instant X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -
Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -
SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>
Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher
FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type:
xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type:
Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based Compensation (Details - Share-based compensation) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended
Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Á Á Á Total stock-based compensation \$ 52 \$
89 \$ 99 \$ 294 Research and Development Expense [Member] Á Á Á Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Á Á Á Total stock-based
compensation 25 51 14 163 General and Administrative Expense [Member] Á Á Á Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Á Á Á Total
stock-based compensation \$ 27 \$ 38 \$ 85 \$ 131 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated
with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-
gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type:
duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-
gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-
gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL
DOCUMENT v3.24.3 Stock-based Compensation (Details Narrative) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based
Compensation Arrangement by Share-Based Payment Award [Line Items] Á Á Á Share-based compensation expense \$ 52,000 \$ 89,000 \$ 99,000 \$ 294,000 Restricted Stock Units (RSUs)
[Member] Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award,
Options, Grants in Period, Net of Forfeitures Á 0 Á 4,833 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date
Fair Value Á Á Á \$ 47.16 Share-based compensation expense 52,000 \$ 89,000 99,000 \$ 294,000 Fair value of awards vested Á Á Á 21,000 100,000 Restricted Stock Units (RSUs) [Member] |
Employees [Member] Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Á Á Á Vesting period Á 1 year Á Share-Based Payment
Arrangement, Option [Member] Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Á Á Á Share-based compensation expense \$ 0 \$ 0 \$ 6,000
\$ 0 Share-Based Payment Arrangement, Option [Member] | Employees [Member] Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Á Á Á
Vesting period Á 4 years Á Share-Based Payment Arrangement, Option [Member] | Non Employee Members [Member] Á Á Á Share-Based Compensation Arrangement by Share-Based
Payment Award [Line Items] Á Á Á Vesting period Á 1 year Á X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1:
<http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit
Period Type: duration X - DefinitionPeriod for which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or
performance condition, in 'PnYnMndTnHnMns' format, for example, 'P1Y3M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to,
combination of market, performance or service condition. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards
Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type:
duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other
instruments, or cash. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -
Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_Data Type:
xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section

[illegible]

[illegible]

row-align: left; text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-wrap; */ .report td.pl.a a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl.a div.a { width: 200px; } .report td.pl.a: hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #a6c; color: black; font-weight: bold; } /* Calendars... */ .report rc { background-color: #0f0f0; } /* Even rows... */ .report re, .report reu { background-color: #def; } .report reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report ro, .report rou { background-color: white; } .report rou td { border-bottom: 1px solid black; } .report rou table td, .report reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html 152 185 1 true 41 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://phiopharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://phiopharma.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) Sheet http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Reconciliation of Cash and Restricted Cash Sheet http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash Reconciliation of Cash and Restricted Cash Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995613 - Disclosure - Organization and Significant Accounting Policies Sheet http://phiopharma.com/role/OrganizationAndSignificantAccountingPolicies Organization and Significant Accounting Policies Notes 10 false false R11.htm 995614 - Disclosure - Collaboration Agreement Sheet http://phiopharma.com/role/CollaborationAgreement Collaboration Agreement Notes 11 false false R12.htm 995615 - Disclosure - Fair Value of Financial Instruments Sheet http://phiopharma.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 12 false false R13.htm 995616 - Disclosure - Leases Sheet http://phiopharma.com/role/Leases Leases Notes 13 false false R14.htm 995617 - Disclosure - Stockholders??? Equity Sheet http://phiopharma.com/role/StockholdersEquity Stockholders??? Equity Notes 14 false false R15.htm 995618 - Disclosure - Stock-based Compensation Sheet http://phiopharma.com/role/StockBasedCompensation Stock-based Compensation Notes 15 false false R16.htm 995619 - Disclosure - Net Loss per Common Share Sheet http://phiopharma.com/role/NetLossPerCommonShare Net Loss per Common Share Notes 16 false false R17.htm 995620 - Disclosure - Subsequent Events Sheet http://phiopharma.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 995621 - Disclosure - Organization and Significant Accounting Policies (Policies) Sheet http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies Organization and Significant Accounting Policies (Policies) Policies http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies 18 false false R19.htm 995622 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://phiopharma.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://phiopharma.com/role/FairValueOfFinancialInstrumentsTables 19 false false R20.htm 995623 - Disclosure - Leases (Tables) Sheet http://phiopharma.com/role/LeasesTables Leases (Tables) Tables http://phiopharma.com/role/LeasesTables 20 false false R21.htm 995624 - Disclosure - Stockholders??? Equity (Tables) Sheet http://phiopharma.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://phiopharma.com/role/StockholdersEquityTables 21 false false R22.htm 995625 - Disclosure - Stock-based Compensation (Tables) Sheet http://phiopharma.com/role/StockBasedCompensationTables Stock-based Compensation (Tables) Tables http://phiopharma.com/role/StockBasedCompensationTables 22 false false R23.htm 995626 - Disclosure - Net Loss per Common Share (Tables) Sheet http://phiopharma.com/role/NetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://phiopharma.com/role/NetLossPerCommonShareTables 23 false false R24.htm 995627 - Disclosure - Organization and Significant Accounting Policies (Details Narrative) Sheet http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesDetailsNarrative Organization and Significant Accounting Policies (Details Narrative) Details http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies 24 false false R25.htm 995628 - Disclosure - Collaboration Agreement (Details Narrative) Sheet http://phiopharma.com/role/CollaborationAgreementDetailsNarrative Collaboration Agreement (Details Narrative) Details http://phiopharma.com/role/CollaborationAgreementDetailsNarrative 25 false false R26.htm 995629 - Disclosure - Fair Value of Financial Instruments - (Details - Financial instruments at fair value) Sheet http://phiopharma.com/role/FairValueOfFinancialInstrumentsDetailsFinancialInstrumentsAtFairValue Fair Value of Financial Instruments - (Details - Financial instruments at fair value) Details http://phiopharma.com/role/FairValueOfFinancialInstrumentsTables 26 false false R27.htm 995630 - Disclosure - Leases (Details - Balance sheet lease items) Sheet http://phiopharma.com/role/LeasesDetailsBalanceSheetLeaseItems Leases (Details - Balance sheet lease items) Details http://phiopharma.com/role/LeasesTables 27 false false R28.htm 995631 - Disclosure - Leases (Details Narrative) Sheet http://phiopharma.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://phiopharma.com/role/LeasesTables 28 false false R29.htm 995632 - Disclosure - Stockholders' Equity (Details - Warrants outstanding) Sheet http://phiopharma.com/role/StockholdersEquityDetailsWarrantsOutstanding Stockholders' Equity (Details - Warrants outstanding) Details 29 false false R30.htm 995633 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://phiopharma.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://phiopharma.com/role/StockholdersEquityTables 30 false false R31.htm 995634 - Disclosure - Stock-based Compensation (Details - RSU activity) Sheet http://phiopharma.com/role/StockBasedCompensationDetailsRsUActivity Stock-based Compensation (Details - RSU activity) Details http://phiopharma.com/role/StockBasedCompensationTables 31 false false R32.htm 995635 - Disclosure - Stock-based Compensation (Details - Option activity) Sheet http://phiopharma.com/role/StockBasedCompensationDetailsOptionActivity Stock-based Compensation (Details - Option activity) Details http://phiopharma.com/role/StockBasedCompensationTables 32 false false R33.htm 995636 - Disclosure - Stock-based Compensation (Details - Share-based compensation) Sheet http://phiopharma.com/role/StockBasedCompensationDetailsShareBasedCompensation Stock-based Compensation (Details - Share-based compensation) Details http://phiopharma.com/role/StockBasedCompensationTables 33 false false R34.htm 995637 - Disclosure - Stock-based Compensation (Details Narrative) Sheet http://phiopharma.com/role/StockBasedCompensationDetailsNarrative Stock-based Compensation (Details Narrative) Details http://phiopharma.com/role/StockBasedCompensationTables 34 false false R35.htm 995638 - Disclosure - Net Loss per Common Share (Details - Antidilutive shares) Sheet http://phiopharma.com/role/NetLossPerCommonShareDetailsAntidilutiveShares Net Loss per Common Share (Details - Antidilutive shares) Details http://phiopharma.com/role/NetLossPerCommonShareTables 35 false false All Reports Book All Reports phio-20240930.xsd phio-20240930.cal.xml phio-20240930_def.xml phio-20240930_lab.xml phio-20240930_pre.xml phio_i10q-093024.htm http://fash.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 53 MetaLinks json IDEA: XBRL DOCUMENT "version": "2.2", "instance": "phio_i10q-093024.htm": { "nsPrefix": "phio", "nsuri": "http://phiopharma.com/20240930", "dts": { "schema": { "local": "phio-20240930.xsd" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/2022-03-31/types.xsd", "https://xbrl.fash.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fash.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/spr/2024/spr-2024.xsd" } }, "calculationLink": { "local": "phio-20240930.cal.xml" }, "definitionLink": { "local": "phio-20240930_def.xml" }, "labelLink": { "local": "phio-20240930_lab.xml" }, "presentationLink": { "local": "phio-20240930_pre.xml" }, "inline": { "local": "phio_i10q-093024.htm" }, "keyStandard": 170, "keyCustom": 15, "axisStandard": 13, "axisCustom": 0, "memberStandard": 13, "memberCustom": 25, "hidden": { "total": 120, "http://fash.org/us-gaap/2024": 115, "http://xbrl.sec.gov/dei/2024": 5, "contextCount": 152, "entityCount": 1, "segmentCount": 41, "elementCount": 403, "unitCount": 5, "baseTaxonomies": { "http://fash.org/us-gaap/2024": 490, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4, "report": { "R1": { "role": "http://phiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "b", "p", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "b", "p", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "R2": { "role": "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000

Reconciliation of Cash and Restricted Cash" isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["id", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "id", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-07-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["id", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-07-01to2024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-07-01to2024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R10": { "role": "http://phiopharma.com/role/OrganizationAndSignificantAccountingPolicies", "longName": "995613 - Disclosure - Organization and Significant Accounting Policies", "shortName": "Organization and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R11": { "role": "http://phiopharma.com/role/CollaborationAgreement", "longName": "995614 - Disclosure - Collaboration Agreement", "shortName": "Collaboration Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R12": { "role": "http://phiopharma.com/role/FairValueOfFinancialInstruments", "longName": "995615 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R13": { "role": "http://phiopharma.com/role/Leases", "longName": "995616 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R14": { "role": "http://phiopharma.com/role/StockholdersEquity", "longName": "995617 - Disclosure - StockholdersEquity", "shortName": "StockholdersEquity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R15": { "role": "http://phiopharma.com/role/Stock-basedCompensation", "longName": "995618 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R16": { "role": "http://phiopharma.com/role/NetLossPerCommonShare", "longName": "995619 - Disclosure - Net Loss per Common Share", "shortName": "Net Loss per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R17": { "role": "http://phiopharma.com/role/SubsequentEvents", "longName": "995620 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R18": { "role": "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies", "longName": "995621 - Disclosure - Organization and Significant Accounting Policies (Policies)", "shortName": "Organization and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "phio i10q-093024.htm", "first": true, "unique": true } }, "R19": { "role": "http://phiopharma.com/role/FairValueOfFinancialInstrumentsTables", "

"http://phiopharma.com/role/FairValueOffinancialInstruments-Details-FinancialInstrumentsAtFairValue", "longName": "995629 - Disclosure - Fair Value of Financial Instruments - (Details - Financial Instruments at fair value)", "shortName": "Fair Value of Financial Instruments - (Details - Financial Instruments at fair value)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "R27": { "role": "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems", "longName": "995630 - Disclosure - Leases (Details - Balance sheet lease items)", "shortName": "Leases (Details - Balance sheet lease items)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "R28": { "role": "http://phiopharma.com/role/LeasesDetailsNarrative", "longName": "995631 - Disclosure - Leases (Details Narrative)", "shortName": "Leases (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true } }, "R29": { "role": "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding", "longName": "995632 - Disclosure - Stockholders' Equity (Details - Warrants outstanding)", "shortName": "Stockholders' Equity (Details - Warrants outstanding)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-12-31 us-gaap:WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span", "p", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31 us-gaap:WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span", "p", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true } }, "R30": { "role": "http://phiopharma.com/role/StockholdersEquityDetailsNarrative", "longName": "995633 - Disclosure - Stockholders' 2019 Equity (Details Narrative)", "shortName": "Stockholders' 2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30 custom_June2023PrefundedWarrantsMember", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "unique": true } }, "R31": { "role": "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "longName": "995634 - Disclosure - Stock-based Compensation (Details - RSU activity)", "shortName": "Stock-based Compensation (Details - RSU activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-12-31 us-gaap:RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31 us-gaap:RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true } }, "R32": { "role": "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity", "longName": "995635 - Disclosure - Stock-based Compensation (Details - Option activity)", "shortName": "Stock-based Compensation (Details - Option activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-12-31 us-gaap:EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31 us-gaap:EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true } }, "R33": { "role": "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation", "longName": "995636 - Disclosure - Stock-based Compensation (Details - Share-based compensation)", "shortName": "Stock-based Compensation (Details - Share-based compensation)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30 us-gaap:ResearchAndDevelopmentExpenseMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "unique": true } }, "R34": { "role": "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative", "longName": "995637 - Disclosure - Stock-based Compensation (Details Narrative)", "shortName": "Stock-based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30 us-gaap:RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "unique": true } }, "R35": { "role": "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares", "longName": "995638 - Disclosure - Net Loss per Common Share (Details - Antidilutive shares)", "shortName": "Net Loss per Common Share (Details - Antidilutive shares)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "phio_i10q-093024.htm", "first": true, "unique": true } }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } }, "auth_ref": ["r29", "r424"] }, "us-gaap:AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). } } }, "auth_ref": ["r29", "r424"] }, "us-gaap:AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). } } }, "auth_ref": ["r30"] }, "ecd:Additional402vDisclosureTextBlock": { "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r483"] }, "us-gaap:AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. } } }, "auth_ref": ["r35", "r424", "r560"] }, "us-gaap:AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. } } }, "auth_ref": ["r329", "r534", "r535", "r536", "r537", "r548", "r561"] }, "ecd:AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r489"] }, "ecd:AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r489"] }, "ecd:AdjToNonPecNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPecNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r489"] }, "ecd:AdjToPecNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPecNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote" } } }, "auth_ref": ["r489"] }, "us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity": { "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld for

label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } } , "auth_ref": ["r6"] } , "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "cldr": "credit", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity"] , "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } } , "auth_ref": ["r26", "r27", "r194"] } , "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "cldr": "debit", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity"] , "lang": { "en-us": { "role": { "negatedLabel": "Cash-in-lieu of fractional shares for reverse stock split", "label": "Cash-in-lieu of fractional shares for reverse stock split", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately." } } } , "auth_ref": ["r6", "r57"] } , "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows"] , "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities." } } } , "auth_ref": [] } , "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } } , "auth_ref": ["r454", "r465", "r475", "r500"] } , "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } } , "auth_ref": ["r457", "r468", "r478", "r503"] } , "phio_AgonOxMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AgonOxMember", "presentation": ["http://phiopharma.com/role/CollaborationAgreementDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Agon Ox [Member]" } } } , "auth_ref": [] } , "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "auth_ref": ["r489"] } , "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "auth_ref": ["r496"] } , "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] , "auth_ref": ["r458", "r469", "r479", "r496", "r504", "r508", "r516"] } , "phio_AmendedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "AmendedWarrants", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Amended warrants" } } } , "auth_ref": [] } , "dei_AmendementDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendementDescription", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } } , "auth_ref": [] } , "dei_AmendementFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } } , "auth_ref": [] } , "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } } , "auth_ref": ["r461"] } , "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares"] , "lang": { "en-us": { "role": { "label": "Antidilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } , "auth_ref": ["r127"] } , "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares"] , "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } } , "auth_ref": ["r13"] } , "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares"] , "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [] } , "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares"] , "lang": { "en-us": { "role": { "label": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } , "auth_ref": ["r13"] } , "phio_April2023FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "April2023FinancingMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "April 2023 Financing [Member]" } } } , "auth_ref": [] } , "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": ["http://phiopharma.com/role/LeasesDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Operating lease footage", "documentation": "Area of a real estate property." } } } , "auth_ref": [] } , "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "cldr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]", "documentation": "Amount of asset recognized for present right to economic benefit." } } } , "auth_ref": ["r62", "r67", "r85", "r101", "r131", "r135", "r144", "r149", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r237", "r239", "r275", "r306", "r360", "r408", "r409", "r424", "r435", "r445", "r453"] } , "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "label": "ASSETS" } } } , "auth_ref": [] } , "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "cldr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } } } , "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } } , "auth_ref": ["r81", "r89", "r101", "r149", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r237", "r239", "r275", "r424", "r435", "r445", "r453"] } , "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "label": "Current assets:" } } } , "auth_ref": [] } , "phio_AssetsLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "AssetsLesseeAbstract", "presentation": ["http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems"] , "lang": { "en-us": { "role": { "label": "Assets" } } } , "auth_ref": [] } , "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } } , "auth_ref": ["r461"] } , "ecd_AwardExrcPrce": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrce", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] , "lang": { "en-us": { "role": { "label": "Exercise Price" } } } , "auth_ref": ["r511"] } , "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] , "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue"], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r549", "r550"] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": ["http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, cash equivalents and restricted cash at the beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of period", "totalLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r9", "r45", "r98"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net decrease in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r45"] }, "phio_CashInLieuOfFractionalSharesForReverseStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "CashInLieuOfFractionalSharesForReverseStockSplit", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash in lieu of fractional shares for reverse stock split", "label": "CashInLieuOfFractionalSharesForReverseStockSplit" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r487"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://phiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding", "http://phiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r78", "r86", "r87", "r88", "r101", "r121", "r122", "r124", "r126", "r133", "r134", "r149", "r156", "r158", "r159", "r160", "r163", "r164", "r169", "r170", "r173", "r176", "r183", "r275", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r348", "r369", "r387", "r392", "r393", "r394", "r395", "r396", "r397", "r538"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r86", "r87", "r88", "r133", "r169", "r170", "r171", "r173", "r176", "r181", "r183", "r324", "r325", "r326", "r327", "r413", "r524", "r531"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r184"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding"], "lang": { "en-us": { "role": { "label": "Warrants outstanding, Beginning balance", "periodEndLabel": "Warrants outstanding, Ending balance", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "phio_ClassOfWarrantOrRightWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding"], "lang": { "en-us": { "role": { "label": "Warrants outstanding weighted average exercise price per share, Beginning balance", "periodEndLabel": "Warrants outstanding weighted average exercise price per share, Ending balance", "label": "ClassOfWarrantOrRightWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "phio_ClinicalCoDevelopmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "ClinicalCoDevelopmentAgreementMember", "presentation": ["http://phiopharma.com/role/CollaborationAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Clinical Co Development Agreement [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r488"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": ["r488"] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://phiopharma.com/role/CollaborationAgreement"], "lang": { "en-us": { "role": { "label": "Collaboration Agreement", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r70", "r72", "r77"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://phiopharma.com/role/CollaborationAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r236"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 2)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r32", "r63", "r307", "r347"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shares of common stock held in abeyance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r34"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r425", "r426", "r427", "r429", "r430", "r431", "r432", "r534", "r535", "r537", "r548", "r559", "r561"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r34"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r34", "r348"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r34"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r6", "r34", "r348", "r366", "r561", "r562"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, \$0.0001 par value, 100,000,000 shares authorized; 958,219 and 416,368 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r34", "r309", "r424"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r493"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r492"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [] }

CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/rpt/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r494"], "ecd CompActualPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActualPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/rpt/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r491"], "us-gaap ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r28", "r403"], "us-gaap ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": ["http://phiopharma.com/role/CollaborationAgreementDetailsNarrative", "lang": { "en-us": { "role": { "label": "Contractual obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": ["f533"], "us-gaap ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": ["r10", "r11", "r12"], "us-gaap ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockNameDomain", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": ["r10", "r11", "r12"], "srct CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://phiopharma.com/role/CollaborationAgreementDetailsNarrative", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "NormalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD--" } } }, "auth_ref": [] }, "us-gaap DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r4", "r131", "r136", "r145", "r408", "r409"], "phio DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://phiopharma.com/role/Stock-basedCompensation", "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r192", "r196", "r223", "r224", "r225", "r417"], "us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "documentation": "DocumentAccountingStandard", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other.'" } } }, "auth_ref": ["r449"], "dei DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r447", "r449", "r461"], "dei DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r448"], "dei DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r436"], "dei DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r449"], "dei DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r449"], "dei DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r482"], "dei DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": [] }, "dei DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://phiopharma.com/role/Cover", "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r439"], "us-gaap EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Net loss per common share.", "verboseLabel": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Net loss per common share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r95", "r109", "r110", "r111", "r112", "r113", "r114", "r119", "r121", "r124", "r125", "r126", "r130", "r232", "r235", "r252", "r253", "r303", "r315", "r404"], "us-gaap EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Net

"Entity Address, State or Province", "documentation": "Name of the state or province." } } } , "auth_ref": [] } , "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } } , "auth_ref": ["r442"] } , "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } } , "auth_ref": ["r438"] } , "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } } , "auth_ref": [] } , "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } , "auth_ref": [] } , "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } } , "auth_ref": ["r438"] } , "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } } , "auth_ref": ["r523"] } , "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } } , "auth_ref": [] } , "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } , "auth_ref": ["r438"] } , "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } } , "auth_ref": [] } , "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } } , "auth_ref": ["r520"] } , "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } } , "auth_ref": ["r461"] } , "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } } , "auth_ref": [] } , "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } } , "auth_ref": ["r438"] } , "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } } , "auth_ref": ["r438"] } , "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } } , "auth_ref": ["r438"] } , "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } } , "auth_ref": ["r438"] } , "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } } , "auth_ref": [] } , "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-O, N-1A." } } } , "auth_ref": ["r521"] } , "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } } , "auth_ref": [] } , "phio_EquityClassifiedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "EquityClassifiedWarrantsMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Equity Classified Warrants [Member]" } } } , "auth_ref": [] } , "us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount", "crdr": "debit", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Increase in fair value of warrants", "documentation": "Amount of increase (decrease) in equity for freestanding written call option classified as equity from modification recognized as equity issuance cost. Includes, but is not limited to, exchange by issuer and holder. Excludes share-based payment arrangement." } } } , "auth_ref": ["r183", "r247", "r249", "r250"] } , "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity"] , "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } } , "auth_ref": ["r6", "r79", "r92", "r93", "r94", "r104", "r105", "r106", "r108", "r113", "r115", "r117", "r132", "r150", "r151", "r152", "r185", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r241", "r242", "r243", "r244", "r245", "r246", "r251", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r293", "r314", "r318", "r319", "r320", "r329", "r387"] } , "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } } , "auth_ref": ["r490"] } , "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } } , "auth_ref": ["r454", "r465", "r475", "r500"] } , "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } } , "auth_ref": ["r451", "r462", "r472", "r497"] } , "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } } , "auth_ref": ["r496"] } , "phio_ExpenseFromContractualObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "ExpenseFromContractualObligations", "crdr": "debit", "presentation": ["http://phiopharma.com/role/CollaborationAgreementDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "[custom:ExpenseFromContractualObligations]" } } } , "auth_ref": [] } , "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } } , "auth_ref": [] } , "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://phiopharma.com/role/FairValueOffFinancialInstrumentsTables"] , "lang": { "en-us": { "role": { "label": "Schedule of financial instruments at fair value", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } } , "auth_ref": ["r549", "r550"] } , "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://phiopharma.com/role/FairValueOffFinancialInstruments-Details-FinancialInstrumentsAtFairValue"] , "lang": { "en-us": { "role": { "documentation": "Class of asset." } } } , "auth_ref": ["r259", "r260", "r261", "r262", "r263", "r264", "r269", "r419"] } , "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://phiopharma.com/role/FairValueOffFinancialInstruments-Details-FinancialInstrumentsAtFairValue"] , "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": ["r259", "r260", "r261", "r262", "r263", "r264", "r269", "r419"] } , "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://phiopharma.com/role/FairValueOffFinancialInstruments-Details-FinancialInstrumentsAtFairValue"] , "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument asset measured at fair value on recurring basis using unobservable input." } } } , "auth_ref": ["r259", "r260", "r261", "r262", "r263", "r264", "r269", "r419"] } , "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://phiopharma.com/role/FairValueOffFinancialInstruments-Details-FinancialInstrumentsAtFairValue"] , "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } } , "auth_ref": ["r259", "r260", "r261", "r262", "r263", "r264", "r269", "r419"] } , "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://phiopharma.com/role/FairValueOffFinancialInstruments-Details-FinancialInstrumentsAtFairValue"] , "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } } , "auth_ref": ["r166", "r186", "r187", "r188", "r189", "r190", "r191", "r254", "r255", "r256", "r257", "r258", "r267", "r268", "r270", "r297", "r298", "r299", "r411", "r412", "r414", "r415", "r416", "r418", "r421"] } , "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } } , "auth_ref": [] } , "us-

```

FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ { "http://phioharma.com/role/FairValueOffFinancialInstruments": { "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r263", "r265", "r266", "r267", "r270", "r271", "r272", "r273", "r274", "r302", "r418", "r422" ] }, "us-gaap FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ { "http://phioharma.com/role/FairValueOffFinancialInstruments-Details-FinancialInstrumentsAtFairValue": { "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r166", "r186", "r191", "r255", "r268", "r297", "r414", "r415", "r416", "r418" ] }, "us-gaap FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ { "http://phioharma.com/role/FairValueOffFinancialInstruments-Details-FinancialInstrumentsAtFairValue": { "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r166", "r186", "r191", "r255", "r256", "r268", "r298", "r411", "r412", "r414", "r415", "r416", "r418" ] }, "us-gaap FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ { "http://phioharma.com/role/FairValueOffFinancialInstruments-Details-FinancialInstrumentsAtFairValue": { "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r166", "r186", "r187", "r188", "r189", "r190", "r191", "r255", "r256", "r257", "r258", "r268", "r299", "r411", "r412", "r414", "r415", "r416", "r418", "r421" ] }, "us-gaap FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ { "http://phioharma.com/role/FairValueOffFinancialInstruments-Details-FinancialInstrumentsAtFairValue": { "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r166", "r186", "r187", "r188", "r189", "r190", "r191", "r254", "r255", "r256", "r257", "r258", "r267", "r268", "r270", "r297", "r298", "r299", "r411", "r412", "r414", "r415", "r416", "r418", "r421" ] }, "ecd ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r458", "r469", "r479", "r504" ] }, "ecd ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r458", "r469", "r479", "r504" ] }, "ecd ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r458", "r469", "r479", "r504" ] }, "ecd ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r458", "r469", "r479", "r504" ] }, "ecd ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r458", "r469", "r479", "r504" ] }, "us-gaap GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 }, "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Loss on disposal of property and equipment", "documentation": "Gain (loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r4" ] }, "us-gaap GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap OperatingExpenses", "weight": 1.0, "order": 2.0 }, "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r41", "r371" ] }, "us-gaap GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ { "http://phioharma.com/role/Stock-basedCompensationDetails-SharesBasedCompensation": { "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r41" ] }, "us-gaap IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "presentation": [ { "http://phioharma.com/role/Stock-basedCompensationDetails-SharesBasedCompensation": { "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [ "r153", "r154", "r155", "r260", "r264", "r269", "r316", "r317", "r372", "r398", "r420", "r558" ] }, "us-gaap IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ { "http://phioharma.com/role/Stock-basedCompensationDetails-SharesBasedCompensation": { "lang": { "en-us": { "role": { "label": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r154", "r155", "r260", "r264", "r269", "r316", "r317", "r372", "r398", "r420", "r558" ] }, "us-gaap IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities." } } }, "auth_ref": [ "r3" ] }, "us-gaap IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": [ { "http://phioharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r525", "r528" ] }, "us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "mon
```


BalanceSheetLeaseItems" }, "lang": { "en-us": { "role": { "label": "Lease Term and Discount Rate" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://phioipharma.com/role/Leases"], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee, includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r283"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://phioipharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://phioipharma.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity 2019", "label": "Liabilities and Stockholders' Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r39", "r64", "r311", "r424", "r532", "r544", "r551"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://phioipharma.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY 2019", "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://phioipharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://phioipharma.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r31", "r82", "r101", "r149", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r238", "r239", "r240", "r275", "r424", "r545", "r553", "r554"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://phioipharma.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current liabilities", "label": "Current liabilities" } } }, "auth_ref": [] }, "phio_LiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://phioipharma.com/20240930", "localname": "LiabilitiesLesseeAbstract", "presentation": ["http://phioipharma.com/role/LeasesDetails-BalanceSheetLeaseItems"], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "auth_ref": [] }, "phio_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://phioipharma.com/20240930", "localname": "LiquidityPolicyTextBlock", "presentation": ["http://phioipharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Liquidity" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://phioipharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "phio_May2024FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://phioipharma.com/20240930", "localname": "May2024FinancingMember", "presentation": ["http://phioipharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "May 2024 Financing [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": ["r488"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": ["r488"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r507"] }, "ecd_MtrTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r515"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r489"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://phioipharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Nature of Operations", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r69", "r76"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://phioipharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://phioipharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r97"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://phioipharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://phioipharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://phioipharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r97"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://phioipharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://phioipharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://phioipharma.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://phioipharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r40", "r47", "r65", "r80", "r90", "r91", "r94", "r101", "r107", "r109", "r110", "r111", "r112", "r113", "r116", "r117", "r123", "r149", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r232", "r235", "r253", "r275", "r313", "r368", "r385", "r386", "r433", "r545"] }, "us-gaap_NewAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyTextBlock", "presentation": ["http://phioipharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting, includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://phioipharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "phio_NonEmployeeMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://phioipharma.com/20240930", "localname": "NonEmployeeMembersMember", "presentation": ["http://phioipharma.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Non Employee Members [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": ["r488"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r486"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r485"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r515"] }, "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r515"] }, "phio_NonCashEquityIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://phioipharma.com/20240930", "localname": "NonCashEquityIssuanceCost", "crdr": "debit", "presentation": ["http://phioipharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Non-cash equity issuance cost" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://phioipharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://phioipharma.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r42"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://phioipharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://phioipharma.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://phioipharma.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://phioipharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://phioipharma.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r66", "r405",

"r539", "r540", "r541", "r542", "r543" }], "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://phiopharma.com/role/LeasesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Operating lease costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r288", "r423"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://phiopharma.com/role/LeasesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Operating lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r552"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems"], "lang": { "en-us": { "role": { "verboseLabel": "Lease liability", "label": "Operating Lease Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r286"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r286"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://phiopharma.com/role/LeasesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Operating Lease Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r287", "r289"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems"], "lang": { "en-us": { "role": { "label": "Right of use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r285"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of right of use asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r529"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems"], "lang": { "en-us": { "role": { "label": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r291", "r423"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems"], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r290", "r423"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": ["http://phiopharma.com/role/OrganizationAndSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Organization and Significant Accounting Policies", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": ["r48", "r49", "r50", "r60"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r84"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r488"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://phiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 17 or Item 18" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r449"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r456", "r467", "r477", "r502"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": ["r459", "r470", "r480", "r505"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r459", "r470", "r480", "r505"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": ["r484"] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": ["http://phiopharma.com/role/LeasesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Total base rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": ["r2"] }, "us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfRedeemablePreferredStock", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Redemption of Series D preferred stock", "label": "Payments for Repurchase of Redeemable Preferred Stock", "documentation": "The cash outflow for reacquisition of callable preferred stock." } } }, "auth_ref": ["r44"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Payment of taxes on net share settlements of restricted stock units", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r96"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Cash paid for purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r43"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r487"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r487"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r486"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": ["r489"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r485"] }, "phio_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "PlacementAgentWarrantsMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants [Member]" } } }, "auth_ref": ["r443"] }, "dei_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r486"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://phiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r443"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://phiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r445"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r33", "r169"] }, "phio_PreferredStockSeriesDMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "PreferredStockSeriesDMember", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Preferred Stock Series D [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r33", "r348"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r33", "r169"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r33", "r348", "r366", "r561", "r562"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [

authorizing: no shares issued and outstanding at September 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } , "auth_ref": ["r33", "r308", "r424"] } , "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } , "presentation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } } , "auth_ref": ["r527"] } , "phio_PreviouslyIssuedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "PreviouslyIssuedWarrantsMember", "presentation": { "http://phiopharma.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Previously Issued Warrants [Member]" } } } , "auth_ref": [] } , "phio_ProceedsFromAmendmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "ProceedsFromAmendmentOfWarrants", "crdr": "debit", "presentation": { "http://phiopharma.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Proceeds from amendment of warrants" } } } , "auth_ref": [] } , "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": { "http://phiopharma.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Gross proceeds from common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } } , "auth_ref": ["r1"] } } , "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } , "presentation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "http://phiopharma.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Net proceeds from the issuance of common stock and warrants", "verboselabel": "Proceeds from equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } } , "auth_ref": ["r1", "r324"] } } , "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://phiopharma.com/role/LeasesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } } , "auth_ref": ["r5", "r292"] } } , "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://phiopharma.com/role/LeasesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": ["r292"] } } , "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } , "presentation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } } , "auth_ref": ["r5", "r292", "r304", "r312", "r424"] } } , "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/role/LeasesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } } , "auth_ref": ["r52", "r292"] } } , "us-gaap_PropertySubjectToOperatingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOperatingLeaseMember", "presentation": { "http://phiopharma.com/role/LeasesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Property Subject to Operating Lease [Member]", "documentation": "Property subject to an operating lease." } } } , "auth_ref": [] } } , "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis", "presentation": { "http://phiopharma.com/role/LeasesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Property Subject to or Available for Operating Lease [Axis]", "documentation": "Information by property that could be leased or is available for lease." } } } , "auth_ref": ["r68"] } } , "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain", "presentation": { "http://phiopharma.com/role/LeasesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "A descriptive title of whether the property is subject to or available for operating lease." } } } , "auth_ref": ["r68"] } } , "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "documentation": "Pay vs Performance Disclosure, Table" } } } , "auth_ref": ["r484"] } } , "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": ["r451", "r462", "r472", "r497"] } , "phio_RedemptionOfPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "RedemptionOfPreferredStock", "crdr": "credit", "presentation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Custom:RedemptionOfPreferredStock" } } } , "auth_ref": [] } , "phio_RegisteredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "RegisteredSharesMember", "presentation": { "http://phiopharma.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Registered Shares [Member]" } } } , "auth_ref": [] } } , "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": { "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative": { "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative": { "auth_ref": ["r102", "r103", "r165", "r171", "r294", "r300", "r305", "r401", "r402"] } } , "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } , "presentation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } } , "auth_ref": ["r226", "r398", "r408", "r555"] } } , "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": { "http://phiopharma.com/role/Stock-basedCompensationDetails-Shares-basedCompensation": { "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } } , "auth_ref": [] } , "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "documentation": "Restatement Determination Date" } } } , "auth_ref": ["r452", "r463", "r473", "r498"] } } , "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } } , "auth_ref": ["r453", "r464", "r474", "r499"] } } , "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } } , "auth_ref": ["r460", "r471", "r481", "r506"] } } , "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } , "presentation": { "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash": { "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } } , "auth_ref": ["r526", "r530", "r556", "r557"] } } , "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares": { "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity": { "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } } , "auth_ref": [] } } , "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/

statements." } } } , "auth_ref": ["r25"] } , "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationTables"] , "lang": { "en-us": { "role": { "label": "Schedule of stock-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } } , "auth_ref": ["r25"] } , "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://phiopharma.com/role/LeasesDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } } , "auth_ref": ["r5", "r292"] } , "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity", "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } } , "auth_ref": ["r193", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222"] } , "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationTables"] , "lang": { "en-us": { "role": { "label": "Summary of RSU's activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } } , "auth_ref": ["r59"] } , "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationTables"] , "lang": { "en-us": { "role": { "label": "Summary of stock options activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } } , "auth_ref": ["r7", "r8", "r59"] } , "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding", "http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } } , "auth_ref": ["r17", "r18", "r19", "r20", "r21", "r22", "r53", "r55", "r56", "r57", "r86", "r87", "r88", "r133", "r169", "r170", "r171", "r173", "r176", "r181", "r183", "r324", "r325", "r326", "r327", "r413", "r524", "r531"] } , "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://phiopharma.com/role/StockholdersEquityTables"] , "lang": { "en-us": { "role": { "label": "Schedule of outstanding warrants", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } } , "auth_ref": ["r23"] } , "us-gaap_SecuritiesFinancingTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionAxis", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Securities Financing Transaction [Axis]", "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost." } } } , "auth_ref": ["r61"] } , "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionTypeDomain", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Measurement of financing transaction securities held." } } } , "auth_ref": ["r61"] } , "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } } , "auth_ref": ["r437"] } , "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } } , "auth_ref": ["r441"] } , "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } } , "auth_ref": ["r440"] } , "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://phiopharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } } , "auth_ref": ["r446"] } , "us-gaap_SegmentReportingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyTextBlock", "presentation": ["http://phiopharma.com/role/OrganizationAndSignificantAccountingPolicies"] , "lang": { "en-us": { "role": { "label": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } } , "auth_ref": ["r137", "r138", "r139", "r140", "r141", "r142", "r143", "r146", "r147", "r406", "r407", "r410"] } , "phio_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "SeriesAWarrantsMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]" } } } , "auth_ref": [] } , "phio_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "SeriesBWarrantsMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Series B Warrants [Member]" } } } , "auth_ref": [] } , "phio_SeriesCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "SeriesCWarrantsMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Series C Warrants [Member]" } } } , "auth_ref": [] } , "phio_SeriesDWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "SeriesDWarrantsMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Series D Warrants [Member]" } } } , "auth_ref": [] } , "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crd": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } } , "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Stock-based compensation", "verboseLabel": "Total stock-based compensation", "terselabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } } , "auth_ref": ["r3"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in PnYnMnDtHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } } , "auth_ref": ["r417"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity"] , "lang": { "en-us": { "role": { "negatedLabel": "Number of restricted stock units, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } } , "auth_ref": ["r213"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity"] , "lang": { "en-us": { "role": { "label": "Weighted- average grant date fair value per share of restricted stock units, Forfeited", "documentation": "The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } } , "auth_ref": ["r213"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity"] , "lang": { "en-us": { "role": { "label": "Number of restricted stock units, Granted and accepted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } } , "auth_ref": ["r211"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity"] , "lang": { "en-us": { "role": { "label": "Weighted- average grant date fair value per share of restricted stock units, Granted and accepted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } } , "auth_ref": ["r211"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity"] , "lang": { "en-us": { "role": { "periodStartLabel": "Number of unvested restricted stock units, Beginning balance", "periodEndLabel": "Number of unvested restricted stock units, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } } , "auth_ref": ["r208", "r209"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity"] , "lang": { "en-us": { "role": { "periodStartLabel": "Weighted- average grant date fair value per share of unvested restricted stock units, Beginning balance", "periodEndLabel": "Weighted- average grant date fair value per share of unvested restricted stock units, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } } , "auth_ref": ["r208", "r209"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [

"http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity"], "lang": { "en-us": { "role": { "negatedLabel": "Number of restricted stock units, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r212"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Fair value of awards vested", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r215"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity"], "lang": { "en-us": { "role": { "label": "Weighted-average grant date fair value per share of restricted stock units, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r212"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r193", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Options exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r202"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Options exercisable, price per share", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r202"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "negatedLabel": "Options expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r207"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Options forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r206"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r547"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r204"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r214"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r24"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning balance", "periodEndLabel": "Options outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r200", "r201"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, price per share, beginning balance", "periodEndLabel": "Options outstanding, price per share, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r200", "r201"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Abeyance shares issued", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": ["r24"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity", "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "http://phiopharma.com/role/StockholdersEquityDetailsNarrative"], "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Options exercised, price per share", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r205"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Options expired, price per share", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r207"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Options forfeited, price per share", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r206"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Options granted, price per share", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r204"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r24"] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r6"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning, shares", "periodEndLabel": "Balance at ending, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [

"http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld for payroll taxes, shares", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" |, "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth ref": ["r48", "r99"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://phiopharma.com/role/Cover" |, "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth ref": ["r444"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding", "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" |, "lang": { "en-us": { "role": { "label": "Class of Stock Axis", "documentation": "Information by the different classes of stock of the entity." } } }, "auth ref": ["r78", "r86", "r87", "r88", "r101", "r121", "r122", "r124", "r126", "r133", "r134", "r149", "r156", "r158", "r159", "r160", "r163", "r164", "r169", "r170", "r173", "r176", "r183", "r275", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r348", "r369", "r387", "r392", "r393", "r394", "r395", "r396", "r524", "r531", "r538"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "Equity Components Axis", "documentation": "Information by component of equity." } } }, "auth ref": ["r6", "r34", "r37", "r38", "r79", "r92", "r93", "r94", "r104", "r105", "r106", "r108", "r113", "r115", "r117", "r132", "r150", "r151", "r152", "r185", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r241", "r242", "r243", "r244", "r245", "r246", "r251", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r293", "r314", "r318", "r319", "r320", "r329", "r387"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r104", "r105", "r106", "r132", "r284", "r301", "r323", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r361", "r362", "r363", "r364", "r363", "r367", "r370", "r371", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r387", "r428"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth ref": ["r104", "r105", "r106", "r132", "r148", "r284", "r301", "r323", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r361", "r362", "r363", "r364", "r363", "r367", "r370", "r371", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r387", "r428"] }, "ecd_StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" |, "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth ref": ["r455", "r466", "r476", "r501"] }, "phio_StockAndWarrantsIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "StockAndWarrantsIssuedDuringPeriodSharesNewIssues", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "monetaryItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "StockAndWarrantsIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "monetaryItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity", "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" |, "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of warrants, shares", "verboseLabel": "Shares of common stock issued related to exercise of pre-funded warrants", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth ref": ["r6", "r19", "r34", "r37", "r57", "r167"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity", "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" |, "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants, net of offering costs, shares", "verboseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth ref": ["r6", "r33", "r34", "r37", "r324", "r387", "r393"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units, shares", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth ref": ["r6", "r33", "r34", "r57"] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "Cash-in-lieu of fractional shares for reverse stock split, shares", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth ref": ["r6"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" |, "lang": { "en-us": { "role": { "label": "Options exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth ref": ["r6", "r33", "r34", "r57", "r205"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of warrants", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth ref": ["r6", "r33", "r34", "r37", "r38", "r57"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants, net of offering costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth ref": ["r6", "r33", "r34", "r57", "r329", "r387", "r393", "r434"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth ref": ["r6", "r57"] }, "phio_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "StockOptionsMember", "presentation": ["http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares", "lang": { "en-us": { "role": { "label": "Stock Options [Member]" } } }, "auth ref": [] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "negatedLabel": "Redemption of preferred stock, shares", "label": "Stock Redeemed or Called During Period, Shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth ref": ["r6"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "negatedLabel": "Redemption of preferred stock", "label": "Stock Redeemed or Called During Period, Value", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth ref": ["r6"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0] }, "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" |, "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth ref": ["r34", "r37", "r38", "r51", "r350", "r366", "r388", "r389", "r424", "r435", "r532", "r544", "r551", "r561"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Stockholders' equity", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth ref": ["r295", "r296"] }, "phio_SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "presentation": ["http://phiopharma.com/role/LeasesTables", "lang": { "en-us": { "role": { "label": "Schedule of lease amounts recorded in balance sheet" } } }, "auth ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth ref": ["r495"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Total Shareholder Return" } } }] }

`"Amount": {}, "auth_ref": ["r487"], "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r494"], "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://phiopharma.com/role/Cover"] }, "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [], "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionDomain", "presentation": ["http://phiopharma.com/role/CollaborationAgreementDetailsNarrative"] }, "http://phiopharma.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": ["r402"], "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionTypeAxis", "presentation": ["http://phiopharma.com/role/CollaborationAgreementDetailsNarrative"] }, "http://phiopharma.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": ["r402"], "ecd_TrdrArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": ["r517"], "ecd_TrdrArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": ["r518"], "ecd_TrdrArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": ["r518"], "ecd_TrdrArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement Individual Name" } } }, "auth_ref": ["r516"], "ecd_TrdrArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": ["r516"], "ecd_TrdrArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": ["r517"], "ecd_UndrvySecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrvySecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": ["r513"], "phio_UnregisteredPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "UnregisteredPreFundedWarrantsMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Unregistered Pre Funded Warrants [Member]" } } }, "auth_ref": [], "phio_UnregisteredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "UnregisteredSharesMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Unregistered Shares [Member]" } } }, "auth_ref": [], "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://phiopharma.com/role/OrganizationAndSignificantAccountingPolicies"] }, "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r14", "r15", "r16", "r71", "r73", "r74", "r75"], "phio_WarrantAmendmentAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "WarrantAmendmentAgreementsMember", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Warrant Amendment Agreements [Member]" } } }, "auth_ref": [], "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares"] }, "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding": { "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r425", "r426", "r429", "r430", "r431", "r432"], "phio_WarrantsExercisedShare": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "WarrantsExercisedShare", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding"] }, "lang": { "en-us": { "role": { "negatedLabel": "Warrants exercised, shares", "label": "Warrants Exercised Share" } } }, "auth_ref": [], "phio_WarrantsExercisedWeightedAverageExercisePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "WarrantsExercisedWeightedAverageExercisePricePerShare", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding"] }, "lang": { "en-us": { "role": { "label": "Warrants exercised weighted average exercise price per share" } } }, "auth_ref": [], "phio_WarrantsExpiredShares": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "WarrantsExpiredShares", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding"] }, "lang": { "en-us": { "role": { "negatedLabel": "Warrants expired, shares", "label": "Warrants Expired Shares" } } }, "auth_ref": [], "phio_WarrantsExpiredWeightedAverageExercisePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "WarrantsExpiredWeightedAverageExercisePricePerShare", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding"] }, "lang": { "en-us": { "role": { "label": "Warrants expired weighted average exercise price per share" } } }, "auth_ref": [], "phio_WarrantsIssuedNewShares": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "WarrantsIssuedNewShares", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Warrant new shares issued" } } }, "auth_ref": [], "phio_WarrantsIssuedShares": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "WarrantsIssuedShares", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding"] }, "lang": { "en-us": { "role": { "label": "Warrants issued, shares" } } }, "auth_ref": [], "phio_WarrantsIssuedWeightedAverageExercisePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://phiopharma.com/20240930", "localname": "WarrantsIssuedWeightedAverageExercisePricePerShare", "presentation": ["http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding"] }, "lang": { "en-us": { "role": { "label": "Warrants issued weighted average exercise price per share" } } }, "auth_ref": [], "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations"] }, "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r120", "r126"], "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations"] }, "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding" } } }, "auth_ref": [], "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations"] }, "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r119", "r126"], "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://phiopharma.com/role/Cover"] }, "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r522"], "std_ref": { "ro": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FAS`

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

!A0+G,KQ,F<21?>(DR,Q+22,M)*9IL=77G2NT'E@B: & 7102,J.E.4*(B\$)0IYH*B*11RQ+M#;7LXL9=)M4-/Z1Z1EJRNLO5,6 H1XB:AC%BD^+2.6:* ,ZUA**& HK90%Y-
NY/T4G>1K&:7,EEI#&:B,1J2U!M/L3,F-410-0F26ZGQ%FO(RCHB)&M6EQ9P>Y)S7^6I:Y*6MP=4)S&67,M.HE5=F=-R,96/!<#&:CKVD:
Q1TVL5>L,Z/3D10Z0Y)S.#,N1J1R1H#&:M<5>A3..LK95,NW2NM4.BC=B8RRC#>=G^K^&OIB2CSMOCR&1121?1AP8# MO">= #0-%YF Y%4">7)EZM<\$(N,4)\$@^I=64,
<M0Q3E6W1V4J22^M/M/300-1*AK,ISX XTBH/23Z6E^D^64/YW/PQ3NR-VPC/TINWY31,@.E01I M12SP(I,Q,PUU@ZK1H>:YV"/>#H1Z/HK-K0>=274R279^27M^1G_V-WD
MZ01L2?<3*&E^G2GHINZD_OIL= 2531516[0^Y>J4IR^1C1W+&TZ,9YRW* MJK1E1Y^LM3J30- K4FN/PPDQ2NA^I:MD>UGOW,=>+LW&:F&H9>BWPZK) M:7J1F13<
#16LOB^1AJCT1RMM^L>7DS%RB^Z)I)M# P1IU>/(B(IXI M.24H7+ET,K.M9&&1UKKD0#)JDXWN7=46TC#ASF@O^H2I^KA64BC(RY+&BT1+&F5 M1_C&_ 'XT#2\$,SFOYS \$&WT^
MV^1%WS=>=2^C1X56M%=&1!&T:53L<772>R>#&:B,1J7?OIHF,571 L#&8:ME1YSKOWY^@6L+E=A=OJ&S*6 X5@G\$1<\$0S\$F4M01^65C:H+
M7LW@<2CYO1=0MN,PHK015%,IGYX0R&:R@I&+K,1,2+1HMO,1:1& 9L^> M11IYE6>8%6I,Q,R>BFL>B7G1@K36UTG0+&G4+P /JNK79UW>PD^>AI^/W MN1IV,?#KSR1H:
5P2)MC%#&BYRRX1=Q3,Z^J1^1:149+0+&26AX9= M#&:@XZ1R1+&B,31U%FSDKY2PVKXZ>,69VPK%PNZ#&:M>Z81,<@>C7E8 M&O:1AGD>1^5, +
2P^1Q03IBU2N:VXS(B@<^J^JW6 +&VOXY M^64,AP7L1TYV> 6FPZP>+&+8,M,N0DH5^92G8^B)MVLX>B06U1Y17V MZAPK^=4D1N^=H-Z2(&6&HRI/OO:Q^B^4+H^,
VN44<^3C^A:,KF9,29I,M-OMAA8MVD85)S^313(L13)@IYW&+&SMN&PDEI25-4+RUR5^L1^8IGU MG:ZRXRF,9C^ZHP=ZKB#&S^W<4F01^5.VPDJHKS:P3FIR#5H-
^UPR@18LU= M^LJOM&3DG:O,OKFR W2SID2 DCWTW1!>KH- MPE^M^G^A81S>+X8>=>SO/LHC3R1^1)1Z2:IN3D+=>#NO-N>OXP H^ NJP MD19FQ%CAO,1C10
UKP9G@<O19>12LOCI+HSFOP96^R)UF6ZDHN=WC2Z, U M3X7AOTID?PCL 60:8WO=>+5>LKI1+&7K\$ZV&3^3S70:7^3)@WM&MY#7) M(+&KU@S:5f4>HS^9YJ1I^
U>F95-4^OIH(MIMM)TLOY^G2\$WSCB1^ETO9 M^#07<#>A:ILG\$3.PBC:=>@R@I8-&812^7&I&T^1^1:V^Y2E(YV3 M4I^F:FXV8^&GC5H)IV4,V3C U6TG(8I\$3?>
J3KEE54UO:U&M832NN1I,M,Q&O^:CL /P01 71R1N70QU^L9X&92ZGS^>G8J3P1,112EW /97U>CZ1 M 01OD:1 &YU /JZ2^NW BWOQU4HC:1C1U6F%99?SW2:~
39303Y&TH2I1W M=RW^LIXQ0Y3KJESLE)VURU7U4.5LD6 MV>:95H^N7%>D^UX05%5 MIAEMW8G8,B,1+>: DE-T62CR)TUR,73#OL(L,R\$NCRJF=F@2E:H1I>=E&
MOGK>T4454+9H VM-BRO2Y+H0KR+O2B@&KMEI794O3H7Z7)I,S 2<=>RG M:(T6D1WMB8<9U8D)C: 620%<1+&OBC1),X4Y1SDX1
ME7Z64Z,M0Q228BD=FOLB&9:W3:#F0,ZLLR^3:0<3&FMND6^3W7),OXC2V M IUWQX1IV56, X< M9H /1^OQJA>10#RF(\$YHW46\$&Y>?:#HL=OM7YVF^WW Z74?
N3X<^U:=M=IAQX59G@VUOVNUO01T,1+9OZ^S71Y Y&S:9FQ191(G816=DKI91+4Q55 M42Q, GK<6K2Q4QU(7U^ZS7YI, J^V1U4)2NKSU7T4 208H1E7:Q08G0GP
M^V^O:2,0=&4,4.3\$=1^90SA^\$93.B1T62=Z#&X1 ^90&=>W91A4G88B1JUG@&:"B^NYMHV MGI6M1E^J^J4P:1X1)-REM(HK,8Q2^M1%&A-D\$(<^141^33)JOP MUsL?
+2+DBZ^8XV=M<@9QI1<^>#9823M^LVJ5:RCIA729POFFHY137\$C^T:52,IZ1IR6@<^L^P 1U-I8H=NI^C1I8@CLM1^MGG^*UE,^ACGX50F695B8TD_M^Y&P
I^U(VEY^KOP05:66BEJ^Z^L1I, M1010.TCW^WRE3=A^1^1>WF2910M,<P/CD09P2L^M^2 1#&2^EAL:Q\$ U70IX^!
M2^>V012^9U#R<+^1.RP>Z5BQ7:VTRR1+&8F:Q^I'N.AQI79WD)TDMG; M+G7^T^3I^O)WG,WP)=ZBM+IBOXCHWID^*>#J^C1I>1^DO#TEH^GC8I,P MKJ4>
JCI1XKWHPLE^E^Z8.FR1FR1-9%Y&D,@/X7WH1@&O9>: !KBYN^IRCMVMY9>P^1V^>2^ IF+>GDPG9,14=RYW81)VOI@^8H2L@<^INTBMTG_1A#2K9, M21B<7
&93<=>JSY^K6G1AP,-&Y=V,^MDI4Q1Y1I>E\$<1^G)IS= MRYV ^9V7P^P1^1,370^O21P^<^CQIG19\$+1K^1<1^6= 4E6
M1S^XR^K,R1RHR4,1,LS\$XS1<K^7\$G@<1^#>^I^F9^>PQ2A-YT5^:B,8CHJ06= M:1D60^CFZ(T,TH^A&<K^1S=43YVUZ>:J\$<1, P3SS114 M6A8)/4#P -GAH#3(PLI)WQC\$S99#A_>
ZYV5H.MJS-<135OP2)TITWY,&MKQ72I8<3I#<+&+3N1J31I, W5^M19E5^Y6M(GK6^P^W0.S^ Y1YUW)ELPA(86ZP)>BDHN? M7K.C1:R\$+&=Q3RI WWTUK5)83
L_V.P8I@<1^Z4M54T@&0%SF694@%70W.GCGV:0QU%4)RODZB?6I=I#WS(MM613P5 /OV:3.804+N,@? J#W(O4.EYO@X^T1KGKQ%V#@<I188^DS9+6NJC M^I>C?>
65\$#ZVLH2#?ITE ,DKJ6OQ:12V1FLB7XG&523138~&M1CM6^61 ML^V^N#J:5=>@1^:1^6F:C7 1U2C1M450+ZAISOWC\$Y221X14&471@J, M^=YAKS1:7#Z1I?>
71Y)95A#NOI>ROO:G^Y5 TL^2 3^6L21#>WOS3 MEYWD6.5A1 E^&#^YU>Z>70 3^&S>SAU\$4&N=P00C 0,0=>@<1L4 B6@<1@&VX^1 M^:VEA2P1JCM<2M^H8PHQ2T^R^22A/
MK158I>Y3+>OT7LK1,B /85Y51&2518W 2UM^1^1^OPM,IPUG X,NW 4&S6< M^1-I438&11J1-H5&9>5A1I)V<@&6KX9H1P1,%04K<8=1Y1 -OLFEA%1%Y0 M4IF/(REG\$Q%M 10:<#1
3HYALOP+&K1>0Y5YN13, :1CFY524V&139#49) MFAD1^LQOP1+&LQ>VYVVOIC^&N21B98RT^64^P^T^KOS1LOFAH=%\$U=IC6(M-M
19=+TY1^Z(SXS.P^"4&@)JHE<1^NF1.X,%UOY@+W@+&1GWB)&^&:~?H M#)99+V<,74PV+21\$SS/OH1>A6F&>2F2I,<+>=>CB1:S^43Y @63^DJ1I^ M9=#+440G1@SS
^1E1RTD8^P5^DGO@+V1@&B^IY6W0#<19,10#&HGD1#<0 MOZV,Y,("ZSEYI^W^ANHS05TB M?@/L11B6^LH:P^C: R4A4A>=R+& MVJ1N, Y^DD 1 4H23DC^0^#<
=>50LRE,M^1+&)>GQ#1>28I^M^1 618B^75C:(MI6.5C/Q>YB^<1^0)D6L1XH?QVTBA=&ISK962H\$&R>M,UTBF99^0/16Y\$1^&^#KU<^>M1321LO1S,%5
CP1(WP:T^K^XCDAS^<^B MV5:V019:1, 31AJL:@A1SM%OF6SN\$<7MC5&SG9REU/RI(= MB2R0414 13Y0&S6H W&0E6ZE^P,=6H+&

[illegible]

(TQK04*13LXE/AH@90K0ZUH,ZL)M%-5K-MG<O:T7Y5B/0CEN(0K):#P<C=MR9;KO+O*.E>/N2#A51/MHXO#*T6LE M7D00Q059*5<@*206>
IPPKQ021VTV;@21ZBNY7;H21V^&NQG&HWEN(G^H=5;M;7+SZ>E^+&S*;20&VADZ0>01>2U1V<+E2+&0KR64ZWZV*9**P<C>^IYW6 MMYRDIJCI
M1*65*14Y2*9; ZEDHUR@10R)127*173>9DILF4R4^F9/1)E^F<><<M^FQXPC&*98V*0URS;Z=^JJB M7U064+^YK/2/I 27A1DI^M^&K+4GMU*ZZ
M318^IKLLMV1+WK1T=&M1F8X8[([U9)5^&1FIRLQHX8HE]9>F7W=5<+1DX>UO MZ30BC;C-1+1326N^U97UHI@>^JZR M*2&N;Q;P;C17/P2PKYKSG&A8DO;QV M+82VT7X;^TB-
PNIS>5*2^M5+G;O6XIOD1NMWYE8&VZ/G>3R00KW2BO &L MSF^NE)%%73#1(LX9;JZWA)<^I(LUB(2^YK9[KH7525]X>F%K&WIA^M^Z5&M4 MO;TH(QH;XT;&9G9*)
*5YD[H0A]U>O 9&S+PFE2<+&^LPM^MPD3036M1^<^MH0@2@>3<D;P3/WT<^K;0;0;6&S*3<5<X R3VHVJRHDPW^USW^PZK^UDMABTD M^3G8^IP@I)O00WR<^O TF7;Y3
TCH<Q0^N;S^AXHJN3Y*8#2>8-EDS ZH MTW^I19<+&^IY<4TZI&XPUG&SBBY<8K<^IZP DAI=L N60URCWG#&M1Y9K6H
MUK<=4P50A1U^W24Y1WOXZLW02>2,KT9YU07KP^WJF^SH6DHG<^N(O+1+T7Z MWEAY)<^H(Z@006US^8L8SU6B JHVH^122915D)>6(CG 0@ MO4XR^H?>
GG(9.9K<+ON;E\$=R^G4PS^DK+5DPR)6^#16Q2\$UV1<^R29^M^>I7>I>GE%&^I&Q\$=L5^#R^U.O.S.*%A6T2I9QUV+<@^VBIHXKR+!+K'
MA.W)554,0;L.LR=-/E@G@B.%V118WF.^048&=(S^8XJ0R 1%+^JK MA^2)<^IA@Q;1#A.@:P6JN^=1MKHB95M^-O=O6CV2JF%>?^JHWYCIU>+<C^I
M;E1J5@>^/E<@*IU^D7WIFU0Q@AJR1#?T0+10&>F7-6&SH@AI@X4-&P&2WYT MRUO.^91W+^2^H2+^>+F#>OOVFXJH.1TT+^MV%#2UY5DUU;H6
>^C^IAJAKWRL&S>^WROI3EOOKY0>ZE>4L4EF9PCMRV MO;1N<IUG7J3O1^H19ZK%M.H.HJ>^91&QO>HFB)PFAJH4EQ>IAE=R.H<^1<039#2WE17>7NCNC=7;S(#
M1Z.P^U1@V M+<^G&BWB30 ^JHHR6<+&3^2I9L8B926J(7H1<K&S6620^T>E.N.M.A/E<^SOE^HJ9M0^#M&C^R^JP Y4H>QC+&5.2;9<+LUM;JPD M^LFF270 M^X^I6A30U6>>#<#<
YH&#R=M^V16<+^C^J2 A^5V1&#(2B#R2I0R0;+<^ISQKZ1W&IP9+2 MEIP&KA B.O?DQ^M^>4^7%W.M.B%YJ;P.P^38M.E5.ZI9W>PFXI0D<^#IF80S5F6G>#<^KT^Q#8FDI2QZ;
MFS;XQ&WQICXQ>^CC;6WW910 P.H;Z:@>N>+I^%CJ>5%&X(NZ74U)XIE M<10<#1HL%U>^F O&8P=4XJDO^V9H?WB!^!+^FC46SQ>+^YE\$^\$UJ7VC25171#^T&8Q;X.H.CHC
7^18H M51^&V@M^>Z%&X16U<#203X57<@<^C.L^I10V1>+^I6G^H M^W^MT<^N^PEZSNXIRI^TL<^T(I)^IR^T/I>+&M= IPA7^LYN=RIZ1^IQC M&QCSQO<^QYIHC6 M&^1HJ
JMYR1G651G%QZ^2BK2>^T^%4WR1N.#A1 MLN15.A&8&8DR720^5^M^I71 OKWRO7P&1^H19ZK%M.H.HJ>^91&QO>HFB)PFAJH4EQ>IAE=R.H<^1<039#2WE17>7NCNC=7;S(#
JH2>+CJP0B9W.C1=W.K.<^MFVZ2C^N^>^YOLK K@OCGB^O16=MSLC8HGV2^Q=2S8I M1Y1P1H^L%1@I+E\$<^&I=4P^6^1TIG^+^10I78WTE9Q%N&AR&F.(C3I
M22N100BR<^N^7B0CRK&D1G18YXF=R^N1/;@5U9WEV.B4^F N27N<^YGM F6I0^<^KQ%>@89\$S.B\$HDX&33W1AUDIM.W2U@R@>27.74%#S.WAP5+1
M^O)+L1Y5KZ2GA.J2DI6GIGRU\$O5>^L>+^S@I&3YWG^&.&L9BK H)S%292.SA2KCW;PH3W2&H.HV<+53R9<L=915(3%36^LADCKK M;IKX^EE4ADIBQ&S?<G-
^W;VJVEIYK<+<+^JIC^I&KDYCY.Y7.YMYGZJH6 M^# 6.D&K3F54Z3YV^I9&U1&M^P^G.D-G^P^PFI3N80G.2^U4L7ZL^M.CZ
M/&4 N5E..^49<^H&RR&D&3^24W^TEW24^T1N&I84J5HTUNT^KY<@8&RN&EM MR^=BZ&5+^RH5.HJ09CEH19FA)AH! E /0T^HK8U4M.8W^FP^+4R98\$Q IMS M8?
*Q%&X=M^&#&R@L^I=U5XV1575DNQ^0H97V>D.2Y6GF\$.235NQU M10^PUOY AJ20IR.E@O537^JZRGX&BM50YV.D@<^I(G101HWU7J2 V#P MB?>0F&FC90>O># 6K#<
^X<^<K19.HKFR^CZKE&N5^BDHJY12<0 MV.O2I^4106;^T<4HRA610ME^C^M^1.6R Q M^C@GB^L R^X<X<^PM&S^L M^1Q>.<^DQN7C=B^1S<@>=56AAH=RIJ=&^RPI-
*=1H480ITSLKHIVY&S^M;9%2G^Q1\$Q(I3UV^WX3XMWA+<63PE)Y@&S.2\$ DXU5+66 +2E.IM5DRP<^M^15%HI^1.2KHP<5N1%>W.VU&N5)?G O^VFD6G<3.5I^<^%W-V1L.GM^N
M&G.&^NWI7^&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1^9^E^?7TAMDLT8 1929=>5P4>^Y LGRXB^2IH MTUQWKI7O-QFW;GLL R-RZP&S^U^NHFSHAJ1^#&FDFJN.XWHTH@M^J;^NKL M10M_P900Q(BB0
M^G&C0\$7F&S.&1%&3<7>15 T35-LUMT72A1+8266^BZ0;9P145)DL5W0^M MNXN;B1^HXL I>+<C^I/M;J@<S^9RIE.Z.BF3A3^PTT+&A&A&QIWOBDXY^+^M^%>#?7@<WE7:9#JN-
@S01L8.CI629.5T6>#<Q(HOHT^Q^R^<^M^VZCPI^K91YI9P15 MSKI7FI@L?>9EF2FJA;KE.H^B00^HIB+N)<^P87Q<C&S<#P34<1H^29 M6J^>#<^Y&XU1Q;
KICN<^&IPW1^YU190H7VC2FLB1>^Z^Z1H6237H%LG(WT(M^C^M1L7YH.H^>2^18B1 3H2O^2.Y(HUXH7682HP&3H)M&5^TYK260%200^@2R MNT2B^F&K6
7X>^H^KKK1^@P1Y124 HWN+1WW OXL R^MUA^H^D-A^3<@<^M^T R4;C^LR>^2\$1B1^@T^A^N^MUSEN^V1+V&H&E;P\$@A^I^GORG^F= A51IRH&N&8&E&F41^N^X G<^M1\$%&U
MIU@<Q5)493@>=^&?&S.FP<1

[illegible]

[illegible]

[#S,C,Q+FAT:M;5!+04 Q0 \("J&EE&\(NIT..H./ " + " M-IP:&EO7V5X,S\(P,BYH=&U02Ps"% ,4 " JAFY9M;/9JOK !D6PD M% @ \\$ -Q <&A;UJL3/Q+3 Y S-R "YH=&U02P4&/ H "%@ " L\(End XML 55 phio:H0q-093024.htm.xml IDEAXBRL DOCUMENT 0001533040 2024-01-01 2024-09-30 0001533040 2024-11-14 0001533040 2024-09-30 0001533040 2024-12-31 0001533040 2024-07-01 2024-09-30 0001533040 2023-07-01 2023-09-30 0001533040 2023-01-01 2023-09-30 0001533040](#)

[phio:PreferredStockSeriesDMember 2023-12-31 0001533040 us-gaap:CommonStockMember 2023-12-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001533040 us-gaap:RetainedEarningsMember 2023-12-31 0001533040 phio:PreferredStockSeriesDMember 2024-03-31 0001533040 us-gaap:CommonStockMember 2024-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001533040 us-gaap:RetainedEarningsMember 2024-03-31 0001533040](#)

[phio:PreferredStockSeriesDMember 2024-06-30 0001533040 us-gaap:CommonStockMember 2024-06-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001533040 us-gaap:RetainedEarningsMember 2024-06-30 0001533040 phio:PreferredStockSeriesDMember 2022-12-31 0001533040 us-gaap:CommonStockMember 2022-12-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001533040 us-gaap:RetainedEarningsMember 2022-12-31 0001533040](#)

[phio:PreferredStockSeriesDMember 2023-03-31 0001533040 us-gaap:CommonStockMember 2023-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001533040 us-gaap:RetainedEarningsMember 2023-03-31 0001533040](#)

[phio:PreferredStockSeriesDMember 2023-06-30 0001533040 us-gaap:CommonStockMember 2023-06-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001533040 us-gaap:RetainedEarningsMember 2023-06-30 0001533040 phio:PreferredStockSeriesDMember 2024-01-01 2024-03-31 0001533040 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001533040 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001533040](#)

[phio:PreferredStockSeriesDMember 2024-04-01 2024-06-30 0001533040 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001533040 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001533040](#)

[phio:PreferredStockSeriesDMember 2024-07-01 2024-09-30 0001533040 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001533040 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001533040](#)

[phio:PreferredStockSeriesDMember 2023-01-01 2023-03-31 0001533040 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001533040 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001533040](#)

[phio:PreferredStockSeriesDMember 2023-04-01 2023-06-30 0001533040 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001533040 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001533040](#)

[phio:PreferredStockSeriesDMember 2023-07-01 2023-09-30 0001533040 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001533040 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001533040](#)

[phio:PreferredStockSeriesDMember 2024-09-30 0001533040 us-gaap:CommonStockMember 2024-09-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001533040 us-gaap:RetainedEarningsMember 2024-09-30 0001533040](#)

[phio:PreferredStockSeriesDMember 2023-09-30 0001533040 us-gaap:CommonStockMember 2023-09-30 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001533040 us-gaap:RetainedEarningsMember 2023-09-30 0001533040](#)

[phio:AgonOxMember phio:ClinicalCoDevelopmentAgreementMember 2024-09-30 0001533040 phio:AgonOxMember phio:ClinicalCoDevelopmentAgreementMember 2024-07-01 2024-09-30 0001533040 phio:AgonOxMember phio:ClinicalCoDevelopmentAgreementMember 2024-01-01 2024-09-30 0001533040](#)

[phio:AgonOxMember phio:ClinicalCoDevelopmentAgreementMember 2023-07-01 2023-09-30 0001533040 phio:AgonOxMember phio:ClinicalCoDevelopmentAgreementMember 2023-01-01 2023-09-30 0001533040 us-gaap:CashAndCashEquivalentsMember 2024-09-30 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0001533040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueInputsLevel2Member 2024-09-30 0001533040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueInputsLevel3Member 2024-09-30 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-03-01 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-02-29 2024-03-01 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-01-01 2024-09-30 0001533040](#)

[phio:LaboratoryFacilityMember us-gaap:PropertySubjectToOperatingLeaseMember 2024-07-01 2024-09-30 0001533040 phio:LaboratoryFacilityMember us-gaap:PropertySubjectToOperatingLeaseMember 2024-01-01 2024-09-30 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-09-30 0001533040 phio:May2024FinancingMember 2024-05-16 0001533040](#)

[phio:May2024FinancingMember 2024-05-15 2024-05-16 0001533040 phio:July2024FinancingMember 2024-07-11 0001533040 phio:July2024FinancingMember 2024-07-11 0001533040 phio:SeriesCWarrantsMember 2024-07-11 0001533040 phio:July2024FinancingMember phio:SeriesDWarrantsMember 2024-07-11 0001533040](#)

[phio:July2024FinancingMember 2024-07-11 0001533040 phio:EquityClassifiedWarrantsMember 2024-07-01 2024-07-31 0001533040 phio:PlacementAgentWarrantsMember 2024-07-01 2024-07-31 0001533040](#)

[phio:July2024AbeyanceSharesMember phio:July2024InducementLetterAgreementMember 2024-07-31 0001533040 phio:July2024AbeyanceSharesMember phio:July2024InducementLetterAgreementMember 2024-07-01 2024-09-30 0001533040](#)

[phio:April2023FinancingMember 2023-04-19 2023-04-20 0001533040 phio:April2023FinancingMember 2023-04-20 0001533040 phio:April2023FinancingMember 2023-04-20 0001533040](#)

[phio:SeriesAWarrantsMember 2023-04-20 0001533040 phio:April2023FinancingMember phio:SeriesBWarrantsMember 2023-04-20 0001533040](#)

[phio:April2023FinancingMember phio:PlacementAgentWarrantsMember 2023-04-20 0001533040 phio:PreviouslyIssuedWarrantsMember phio:April2023FinancingMember 2023-04-19 2023-04-20 0001533040](#)

[phio:PreviouslyIssuedWarrantsMember phio:April2023FinancingMember 2023-04-20 0001533040 phio:June2023FinancingMember phio:RegisteredSharesMember 2023-06-01 2023-06-02 0001533040](#)

[phio:June2023FinancingMember phio:UnregisteredSharesMember 2023-06-01 2023-06-02 0001](#)

SegmentReportingPolicyTextBlock zGvsEbTulve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Segments</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates as one operating segment and all assets are located in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p id="xdx 84D eus-gaap--UseOfEstimates zZ6KpsKfsvc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, and the valuation allowance on the Company's deferred tax assets. On an ongoing basis the Company evaluates its estimates and bases its estimates on historical experience and other relevant assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p id="xdx 845 ecustom--LiquidityPolicyTextBlock zAIHhyNhrWgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidity</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has reported recurring losses from operations since its inception and expects to continue to have negative cash flows from operations for the foreseeable future. Historically, the Company's primary source of funding has been from sales of its securities. The Company's ability to continue to fund its operations is dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain its operations. This is dependent on a number of factors, including the market demand or liquidity of the Company's common stock. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back or terminate its operations or seek to merge with or to be acquired by another company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has limited cash resources, has reported recurring losses from operations since inception, has negative operating cash flows and has not yet received product revenues. These factors raise substantial doubt regarding the Company's ability to continue as a going concern, and the Company's current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of these condensed consolidated financial statements. The continuation of the Company as a going concern depends upon the Company's ability to raise additional capital through an equity offering, debt offering and/or strategic opportunity to fund its operations. There can be no assurance that the Company will be successful in accomplishing these plans in order to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p id="xdx 84F eus-gaap--SignificantAccountingPoliciesTextBlock zFYjBxw3JZj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Summary of Significant Accounting Policies</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as set forth above, there have been no material changes to the significant accounting policies disclosed in the Company's 2023 Form 10-K.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><i>Recent Accounting Pronouncements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") 2023-07, "Segment Reporting (Topic 280) – Improvements to Reporting Segment Disclosures" ("ASU 2023-07"), which requires disclosure of incremental segment information on an annual and interim basis. In addition, ASU 2023-07 clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced disclosures are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements and disclosures, but does not expect that it will have a material impact on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) – Improvements to Income Tax Disclosures" ("ASU 2023-09"), which requires disclosure of specific categories in the rate reconciliation table along with additional information for reconciling items that meet a quantitative threshold, disclosure of disaggregated income taxes paid and modifies other income tax-related disclosures. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-09, but does not expect that it will have a material impact on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p id="xdx 84D eus-gaap--NatureOfOperations z0ht6t2UWLXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Nature of Operations</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phio Pharmaceuticals Corp. ("Phio") or the "Company") is a clinical stage biotechnology company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phio was incorporated in the state of Delaware in 2011 as RXi Pharmaceuticals Corporation. On November 19, 2018, the Company changed its name to Phio Pharmaceuticals Corp., to reflect its transition from a platform company to one that is fully committed to developing groundbreaking immuno-oncology therapeutics.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="background-color: white">Effective July 5, 2024, the Company completed a 1-for-9 reverse stock split of the Company's outstanding common stock, including reclassifying an amount equal to the reduction in par value to additional paid-in capital. The reverse stock split did not reduce the number of authorized shares of the Company's common or preferred stock. All share and per share amounts have been adjusted to give effect to the reverse stock split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p id="xdx 845 eus-gaap--BasisOfAccountingPolicyTextBlock zYg5dS4K3VQq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Basis of Presentation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). Certain information and footnote disclosures that are included in the Company's annual consolidated financial statements, but that are not required for interim reporting purposes, have been condensed or omitted. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's most recent Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the "SEC") on April 1, 2024 (the "2023 Form 10-K"). Interim results are not necessarily indicative of results for a full year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p id="xdx 84B eus-gaap--ConsolidationPolicyTextBlock zb4NFMjGFPhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Principles of Consolidation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p id="xdx 846 eus-gaap--SegmentReportingPolicyTextBlock zGvsEbTulve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Segments</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates as one operating segment and all assets are located in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p id="xdx 84D eus-gaap--UseOfEstimates zZ6KpsKfsvc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, and the valuation allowance on the Company's deferred tax assets. On an ongoing basis the Company evaluates its estimates and bases its estimates on historical experience and other relevant assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><p id="xdx 845 ecustom--LiquidityPolicyTextBlock zAIHhyNhrWgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidity</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has reported recurring losses from operations since its inception and expects to continue to have negative cash flows from operations for the foreseeable future. Historically, the Company's primary source of funding has been from sales of its securities. The Company's ability to continue to fund its operations is dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain its operations. This is dependent on a number of factors, including the market demand or liquidity of the Company's common stock. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back or terminate its operations or seek to merge with or to be acquired by another company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has limited cash resources, has reported recurring losses from operations since inception, has negative operating cash flows and has not yet received product revenues. These factors raise substantial doubt regarding the Company's ability to continue as a going concern, and the Company's current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of these condensed consolidated financial statements. The continuation of the Company as a going concern depends upon the Company's ability to raise additional capital through an equity offering, debt offering and/or strategic opportunity to fund its operations. There can be no assurance that the Company will be successful in accomplishing these plans in order to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font: 10pt Times New

[illegible]

[illegible]

[illegible]

"Exercise price">48.60 per share and unregistered eighteen month term Series B warrants to purchase up to 39,331 shares of common stock at an exercise price of \$48.60 per share (collectively, the "April 2023 Financing"). In addition, the Company issued unregistered warrants to the placement agent, H.C. Wainwright & Co., LLC ("HCW"), in the April 2023 Financing to purchase a total of 2,950 shares of common stock at an exercise price of \$63.56 per share. Net proceeds to the Company from the April 2023 Financing were \$1,538,000 after deducting placement agent fees and offering expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in">In connection with the April 2023 Financing, the Company entered into warrant amendment agreements (the "Warrant Amendment Agreements") with the participating investors to amend the exercise price of certain existing warrants to purchase up to an aggregate of 48.60 per share. The Company received \$23,952 as consideration in connection with the Warrant Amendment Agreements. The Company assessed the amendments to the exercise price of the warrants under ASC Topic 815, "Derivatives and Hedging" ("ASC 815") and determined that the amendment to the exercise price was completed in connection with and contingent on the close of the April 2023 Financing. The increase in fair value of \$293,000 related to the Warrant Amendment Agreements was recognized as an equity issuance cost and recorded in additional paid in capital per ASC 815.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"><i>On June 2, 2023, the Company completed a registered direct offering and a concurrent private placement of a total of 25,961 registered shares and 8,000 unregistered shares of the Company's common stock each at a purchase price per share of \$38.52, unregistered pre-funded warrants to purchase up to an aggregate of 69,881 shares of common stock at a purchase price per share of \$38.511 and with a pre-funded warrant exercise price of \$0.009 per share, unregistered five and one-half year term Series A warrants to purchase up to an aggregate of 103,842 shares of common stock at an exercise price of \$36.27 per share and unregistered eighteen month term Series B warrants to purchase up to an aggregate of 103,842 shares of common stock at an exercise price of \$36.27 per share (collectively, the "June 2023 Financing"). In addition, the Company issued unregistered warrants to the placement agent, HCW, in the June 2023 Financing to purchase a total of 7,798 shares of common stock at an exercise price of \$48.15 per share. Net proceeds to the Company from the June 2023 Financing were \$3,510,000 after deducting placement agent fees and offering expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"><i>In December 2023, the Company entered into an inducement letter agreement (the "December 2023 Inducement Letter Agreement") with certain holders of the Company's existing warrants to purchase up to an aggregate of 236,695 shares of the Company's common stock (the "December 2023 Financing"). Pursuant to the terms of the December 2023 Inducement Letter Agreement, in the event that the exercise of the existing warrants in the December 2023 Financing would have otherwise caused a holder to exceed the beneficial ownership limitations set forth in the existing warrant, the Company issued the number of shares that would not cause a holder to exceed such beneficial ownership limitation and agreed to hold such balance of shares of common stock in abeyance. Accordingly, an aggregate of 91,820 shares of common stock were held in abeyance (the "December 2023 Abeyance Shares") with such December 2023 Abeyance Shares evidenced through the holder's existing warrants and which were deemed to be prepaid. The December 2023 Abeyance Shares were held until notice was received by the holder that the balance of the shares of common stock could be issued in compliance with such beneficial ownership limitations and were exercised pursuant to a notice of exercise from the holder. Until such time, the December 2023 Abeyance Shares were evidenced through the holder's existing warrants and have been included in the Company's table of outstanding warrants below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"><i>Pursuant to the terms of the Inducement Letter Agreement, in the event that the exercise of the existing warrants in the December 2023 Financing would have otherwise caused a holder to exceed the beneficial ownership limitations set forth in the existing warrant, the Company issued the number of shares that would not cause a holder to exceed such beneficial ownership limitation and agreed to hold such balance of shares of common stock in abeyance. Accordingly, at December 31, 2023, an aggregate of 91,919 shares of common stock were held in abeyance (the "Abeyance Shares") with such Abeyance Shares evidenced through the holder's existing warrants and which are deemed to be prepaid. The Abeyance Shares will be held until notice is received by the holder that the balance of the shares of common stock may be issued in compliance with such beneficial ownership limitations and may be exercised pursuant to a notice of exercise from the holder. Until such time, the Abeyance Shares are evidenced through the holder's existing warrants and have been included in the Company's table of outstanding warrants below. The remainder of the December 2023 Abeyance Shares were subsequently released during the first quarter of 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"><i>Warrants</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; text-align: justify; text-indent: 0.5in"><i>The Company first assesses warrants that are issued by the Company under the FASB ASC Topic 480, "Distinguishing Liabilities from Equity" ("ASC 480") to determine whether the warrants are within the scope of ASC 480. If there are no instances outside of the Company's control that could require cash settlement, the Company then applies and follows the applicable accounting guidance in ASC

[illegible]

[illegible]

AwardTypeAxis_us-gaap-EmployeeStockOptionMember_zGxQ1maNjxW9" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired, price per share">598.313.35</td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"></td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 2.5pt; text-align: left">Balance at September 30, 2024</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98F_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iFpip0_c20240101_20240930_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_z588sM3EYfWb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">1.133</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98A_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iFpip0_c20240101_20240930_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_zSK9HGCjYrBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, price per share, ending balance">3.371.79</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98D_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iFpn3n3_d0_c20240930_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_zF1RtLhHLZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding"></td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(238,238,238)"><td style="padding-bottom: 2.5pt; text-align: left">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98A_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iFpip0_c20240930_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_zpBptER2KOh8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">1.133</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98B_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iFpip0_c20240930_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_zVMowM72PDYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, price per share">3.371.79</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98B_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1_iFpn3n3_d0_c20240930_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_zJG4sX7hLO5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable"></td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr><tr><td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&>Stock-based compensation expense related to stock options for the nine months ended September 30, 2024 was 6,000. The Company did no have any stock-based compensation expense related to stock options for the three months ended September 30, 2024 and 2023 or the nine months ended September 30, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth total stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023, in thousands:</p><table cellpadding="0" cellspacing="0" id="xdx_989_eus-gaap-ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zdTtbpIU2IPc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr><td colspan="2">Summary</td><td colspan="2">Disclosure - Stock-based Compensation (Details - Share-based compensation)</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2">Schedule of stock-based compensation expense</td></tr><tr><td colspan="2">Schedule of stock-based compensation expense</td><td colspan="2"><span id="xdx_9

[illegible]

[illegible]

black 1pt solid; text-align: right title="Antidilutive shares">357,481</td><td></td></tr><tr style="vertical-align: bottom; background-color: white"><td>Total</td><td><td id="xds_98f_eus-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20240101_20240930_zVaA1SeXHSjH5" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares">1,270,019</td><td></td><td><td id="xds_98f_eus-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c2030101_20230930_z1qVQrr4KsS7" style="border-bottom: black 2.25pt double; text-align: right" title="Antidilutive shares">365,189</td><td></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

The weighted average number of common shares outstanding as of September 30, 2023 includes pre-funded warrants issued in the June 2023 Financing because the exercise of such warrants requires only nominal consideration. Therefore, these pre-funded warrants are not included in the table above.

The weighted average number of common shares outstanding as of September 30, 2024 includes the Abyeance Shares from the July 2024 Financing, the exercise of which was prepaid and requires no further consideration for the delivery of the shares of common stock. Therefore, 97,000 of these Abyeance Shares are not included in the table above.

Subsequent EventsTextBlock zoSFhyllCvmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

In accordance with ASC Topic 855, "Subsequent Events," which establishes general standards of accounting for and disclosure of events that occur after the consolidated balance sheet date but before the consolidated financial statements are issued, the Company has evaluated all events or transactions that occurred after September 30, 2024, up through the date the Company issued the condensed consolidated financial statements.

The weighted average number of common shares outstanding as of September 30, 2023 includes pre-funded warrants issued in the June 2023 Financing because the exercise of such warrants requires only nominal consideration. Therefore, these pre-funded warrants are not included in the table above.

The weighted average number of common shares outstanding as of September 30, 2024 includes the Abyeance Shares from the July 2024 Financing, the exercise of which was prepaid and requires no further consideration for the delivery of the shares of common stock. Therefore, 97,000 of these Abyeance Shares are not included in the table above."